# TOPIRAMATE- topiramate tablet Advanced Rx Pharmacy of Tennessee, LLC

# HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TOPIRAMATE TABLETS safely and effectively. See full prescribing information for TOPIRAMATE TABLETS.

# TOPIRAMATE tablets, for oral use Initial U.S. Approval: 1996

None ( 4)

- Initial U.S. Approval: 1996
  RECENT MAJOR CHANGES
  Warnings and Precautions (5.1.5.4, 5.7.5.10, 5.13) 11/2022
  Topiramate tablets are indicated for:
  INDICATONOS AND USAGE
  Topiramate tablets are provided on the treatment of partial-onset or primary generalized tonic-clonic
  sectors in patients 2 years of age and older (1.1), adjunctive therapy for the treatment of partialsyndrome in patients 2 years of age and older (1.1, adjunctive therapy for the treatment of partialsyndrome in patients 2 years of age and older (1.2), so is returned associated with Lennox-Gastaut
  Preventive treatment of migraine in patients 12 years of age and older (1.3)

Topiramate tablets initial dose, titration, and recommended maintenance dose varies by indication and age group. See Full Prescribing information for recommended dosage, and dosing considerations in patients with real impairment, genative patients, and patients undergoing hemodialysis (2.1, 2.2, 2.3, 2.4, 2.5, 6)

# DOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 50 mg, 100 mg, and 200 mg ( 3)

CONTRAINDICATIONS

- None (-1).
   WARNINGS AND PRECAUTIONS

   Acute myopia and secondary angle closure glaucoma: can lead to permanent visual loss; discontinue topiamate tablets as soon as possible (-5, 1)

   Oligohidrissis and hyperthermits: monitor observased sweating and increased body temperature, especially in pediatric patients (-5, 3)

   Objective and the pediatric patients (-5, 3)

   Metabolic acidosis: baseline and periodic measurement of serum bicarbonate (-5, 4)

   Subcidia behavior and ideation: antepieptic drugs increase the risk of suckial behavior or ideation (-5, 5)

   Subcidia behavior and ideation: antepieptic drugs increase the risk of suckial behavior or ideation (-5, 5)

- Suicidal behavior and ideation: antiepilepit chugs increase the risk of suicidal behavior or ideation (5.5) Cognithe/memoryschiattic adverse reactions: use callon when operating machinely including cars; depression and mood problems may occur (5.6) immed to cieft lip and/or paties, and being small for econgenital malformations, including but not limited to cieft lip and/or paties, and being small for gestational age (5.7). Withdrawal of AEDs: withdraw topiramate tablets gradually (5.8) Decrease ii Bone Mineral Density, has been shown to decrease bone mineral density and bone mineral content in pediatric patients (5.5). Decrease ii Bone micerial pediatric patients (5.5). Serious skin reactions: if Sijs or TEN is suspected, discontinue topiramate tablets (5.11) Hyperammomenia/encephilopathy: measure ammonial if encephilopathic symptoms occur (5.12) Kidney stones: avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidoss; or in patients on a lateogenic dire (5.13) Hyperammomenia during topiramate tablets (5.13) Hyperammomenia during topiramate tablets (5.13) Hyperammomenia (5.13) entity of the suspected of the carbonic anhydrase inhibitors, drugs causing metabolic acidoss; or in patients on a lateogenic dire (5.13) Hyperammomenia during topiramate tratement with concomitant valproic acid use (5.14)

concomitant valprois acid use (5.14)
ADVERSE REACTIONS
Exilency: Most common (\_2.0% more frequent than placebo or low-dose topizimate tablets) adverse
reactions in adult and pediatic patients were: parestinesis, anorexis, weight loss, speech diorders/related
speech problems, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, abnormal vision
and rever (6.3)
To report SUSPECTED ADVERSE REACTIONS, contact Cipia Ltd, at 1.866-604-3268 or FDA at
1.806-FDA.1088 dorwnid.fag. VMDI INTERACTIONS.
Contact Cipia Ltd, at 1.866-604-3268 or FDA at
1.806-FDA.1088 dorwnid.fag.vml (7.4)
Contact and the reaction in adult and reaction in adult and the origin adult and reaction (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Cipia Ltd, at 1.866-604-3268 or FDA at
1.806-FDA.1088 dorwnid.fag.vml (7.4)
Contact and the reaction and the reaction in adult and the reaction in adult and the reaction (6.1)
Contact and the reaction and the reaction in adult and the reaction in

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 2/2024

# FULL PRESCRIBING INFORMATION: CONTENTS\* 1 INDICATIONS AND USAGE

# 1.1 Monotherapy Epilepsy 1.2 Adjunctive Therapy Epilepsy

- 2 DOSAGE AND ADMINISTRATION
- 2.1 Dosing in Monotherapy Epilepsy 2.2 Dosing in Adjunctive Therapy Epilepsy 2.3 Dosing for the Preventive Treatment of Migraine
- 2.3 Dosing for the Preventive Treatment of Migr. 2.4 Administration Information 2.5 Dosing in Patients with Renal Impairment 3.6 Dosing in Patients Undergoing Hemodalysis 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5.1 Acute Myopia and Secondary Angle Closure 5.2 Visual Field Defects

- lary Angle Closure Glaucoma Syndrome
- 5.3 Oligohidrosis and Hyperthermia

- 5.3 Oligohidrosis and Hyperthermia 5.4 Metabolic Acidosis 5.5 Suicidal Behavior and Ideation 5.6 Cognitive/Neuropsychiatric Adverse Reactions 5.7 Fetal Toxicity 5.8 Withdrawal of Antiepieptic Drugs 5.9 Decrease in Bone Mineral Density 5.10 Negative Effects on the Growth (Height and Weight) 5.11 Serious Skin Reactions 5.12 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid Use)
- 5.13 Kidney Stones 5.13 Kidney Stones 5.14 Hypothermia with Concomitant Valproic Acid Use 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS

- 7.1 Antiepileptic Drugs 7.2 Other Carbonic Anhydr 7.3 CNS Depressants ase Inhihitors
- 7.4 Contraceptives
- 7.5 Hydrochlorothiazide (HCTZ)
- 7.6 Pioglitazone 7.7 Lithium

# 7.8 Amitriptyline 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.3 Females and Males of Reproductive
   8.4 Pediatric Use
   8.5 Renal Impairment
   8.7 Patients Undergoing Hemodialysis
   10 OVERDOSAGE
   11 DESCRIPTION
   12.1 Mechanism of Action
   12.2. Pharmacolynamics
   13 a Pharmacolynamics
   13 a Pharmacolynamics

- 12.3 Pharmacokinetics 13 NON-CLINICAL TOXICOLOGY
- I. S NUN-CLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
   14 CLINICAL STUDIES
   14.1 Monotherapy Epilepsy
   14.2 Adjunctive Therapy Epilepsy
   14.3 Preventive Treatment of Migraine
   16 How SUPPLIED/STORAGE AND HANDLING
   16.1 How Supplied
   16.2 Storage and Handling
   17 DATEMPORENTIAL

16.1 How Supplied 16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION 17 PATIENT COUNSELING INFORMATION

### FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

# 1.1 Monotherapy Epilepsy

Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older.

# 1.2 Adjunctive Therapy Epilepsy

Topiramate tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalzed tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older.

### 1.3 Migraine

Topiramate tablets are indicated for the preventive treatment of migraine in patients 12 years of age and older.

#### 2 DOSAGE AND ADMINISTRATION

2.1 Dosing in Monotherapy Epilepsy

#### Adults and Pediatric Patients 10 Years of Age and Older

The recommended dose for topiramate tablets monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. The dose should be achieved by titration according to the following schedule (Table 1):

#### Table 1: Monotherapy Titration Schedule for Adults and Pediatric

Patients 10 years and older			
	Morning Dose	Evening Dose	
Week 1	25 mg	25 mg	
Week 2	50 mg	50 mg	
Week 3	75 mg	75 mg	
Week 4	100 mg	100 mg	
Week 5	150 mg	150 mg	
Week 6	200 mg	200 mg	

# Pediatric Patients 2 to 9 Years of Age

Pedatric Patients 2 to 9 Years of Age Dosing in patients 2 to 9 years of Age based on weight. During the thration period, the initial dose of topiramate tablet is 25 mg/day nightly for the first week. Based upon tolerability, the dosage can be increased to 50 mg/day each subsequent week as tolerated. Thration to the minimum maintenance dose should be attempted over 5-7 weeks of the total thration period. Based upon tolerability and clinical response, additional thration to higher dose (up to the maximum maintenance dose) can be attempted at 25-50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight (Table 2).

# Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age

## -

Weight (kg)	Minimum Maintenance Dose	Maximum Maintenance Dose
Up to 11	150	250
12 - 22	200	300
23 - 31	200	350
32 - 38	250	350
Greater than 38	250	400
* Administered in	n two equally divided doses	

#### 2.2 Dosing in Adjunctive Therapy Epilepsy

#### Adults (17 Years of Age and Older)

House TUT Tests of the and other in the recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by thration to an effective dose in increments of 25 to 50 mg/day every week. Thrating in increments of 25 mg/day every week may delay the tim to reach an effective dose. Doses above 400 mg/day have not been shown to improve responses in adults with partial-onset seizures. the time

#### Pediatric Patients 2 to 16 Years of Age

The recommended total daily dose of topiramate tablets as adjunctive therapy for pediatric patients 2 to 16 years of age with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lenonx-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Trration should begin at 25 mg/kg/day loss, based on a range of 1 to 3 mg/kg/day nightly for the first week. The dosage should then be increased at 1- or 2-week Intervals by increments of 1 to 3 mg/kg/day administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome. The total daily dose should not exceed 400 mg/day. exceed 400 mg/day

#### 2.3 Dosing for the Preventive Treatment of Migraine

The recommended total daily dose of topiramate tablets as treatment for patients 12 years of age and older for the preventive treatment of migraine is 100 mg/day administered in two divided doses (Table 3). The recommended thration rate for topiramate tablets for the preventive treatment of migraine is as follows:

# Table 3: Preventive Treatment of Migraine Titration Schedule for Patients 12 Years of Age and Older

rations in age and order			
	Morning Dose	Evening Dose	
Week 1	None	25 mg	
Week 2	25 mg	25 mg	
Week 3	25 mg	50 mg	
Week 4	50 mg	50 mg	

Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.

## 2.4 Administration Information

Topiramate tablets can be taken without regard to meals

Topiramate tablets Because of the bitter taste, tablets should not be broken

# 2.5 Dosing in Patients with Renal Impairment

In patients with renal impairment (creatinine clearance less than 70 mL/min/1.73 m<sup>2</sup>), one-half of the usual adult dose of topiramate tablets is recommended [see Use in Specific Populations ( 8.5, 8.6), Clinical Pharmacology ( 12.3)].

# 2.6 Dosing in Patients Undergoing Hemodialysis

To avoid rapid drops in topiramete plasma concentration during hemodialysis, a supplemental dose of topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed [see Use in Specific Populations ( 8.7), Clinical Pharmacology ( 12.3)].

# 3 DOSAGE FORMS AND STRENGTHS

Topiramate tablets, USP are available in the following strengths and colors: 25 mg, White colored, circular, biconvex film-coated tablets, debossed with "122" on one side and "C" on the other side.

50 mg, Light orange colored, circular, biconvex, film-coated tablets, debossed with "123" on one side and "C" on the other side.

100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side.

200 mg, Pink colored, capsule shaped, biconvex, film-coated tablets, debossed with "125" on one side and "Cipla" on other side.

## 4 CONTRAINDICATIONS

None

# 5 WARNINGS AND PRECAUTIONS

5.1 Acute Myopia and Secondary Angle Closure Glaucoma Syndr A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate tablets. Symptoms include acute onset of decreased visual acuty and/or ocular pain. Opthhalmologic findings can

include some or all of the following: myopia, mydriasis, anterior chamber shallowing, ocular hyperemia (redness), choroidal detachments, retinal pigment epithelial detachments, macular striae, and increased intraocular pressure. This syndrome may be associated with supractiliary effusion resulting in anterior displacement of the lens and tris, with secondary angle closure glaucema. Symptoms typically occur within 1 month of the supersonal system of the supersonal system of the supersonal system. Its, with secondary angle closure glacuma. Symptoms typicany occur within a month of initiating topismate tablest therapy. In contrast to primary narrow angle glacuma, which is rare under 40 years of age, secondary angle closure glacucma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of topiramate tablets as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of topiramate tablets, may be helpful.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

## 5.2 Visual Field Defects

Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trials and in postmarketing experience in patients receiving topiramate. In clinical trials, most of these events were reversible after topiramate descontinuation. If visual problems occur at any time during topiramate treatment, consideration should be given to discontinuing the drug.

#### 5.3 Oligohidrosis and Hyperthermia

Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with topiramate tablets use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

The majority of the reports have been in pediatric patients. Patients (especially pediatric patients) treated with topiramate tablets should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when topiramate tablet is given with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.

#### 5.4 Metabolic Acidosis

5.4 Metabolic Acidosis
Topiramate can cause hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkabis). This metabolic acidosis is caused by renal bicarbonate loss due to carbonic anhydrase hibibiton by topiramate. Topiramate: acidosis can occur at any time during treatment. Bicarbonate decrements are usually mili-moderate (average decreases of 4 mEq.). It addits and adults and at approximately to milicarbonate to values below 10 mEq/L. Conditions or therapites that predispose patients to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, ketonis was compandi, becardin adulti and additive to the bicarbonate lowering effects of topiramate.

Metabolic actions was commonly observed in adult and pediatric patients treated with topiramate in clinical trials. The incidence of decreased serum bicarbonate in pediatric trials, for adjunctive treatment of Lennox-Gastaut syndrome or refractory partial-onses seizures was as high as 67% for topiramate (at approximately 6 mg/kg/day), and 10% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value < 17 mEq/L and  $\ge$  5 mEq/L decrease from pretreatment) in these trials was up to 11%, compared to  $\le$ 2% for placebo.

Manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelee including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients treated with topiramate demonstrated that topiramate decreased lumbar spine bone mineral density and that this lumbar spine bone mineral density decrease was correlated (using change from baseline for lumbar spine z sore at final vist versus lowest post-treatment serum bicarbonate) with decreased serum bicarbonate, a reflection of metabolic acidosis in pediatric patients (5.9). *Use in Specific Populations ( 8.41)*. Chronic metabolic acidosis in pediatric patients may decrease efficiency of pediatric patients the maximal height achieved. Long-term, open-babel treatment of pediatric patients 1 to 24 months old with intractable partial epilepsy, for up to 1 year, showed reductions from baseline in length, weight, and head circumference compared to age and sex-matched normative data, although these patients with epilepsy are likely to have different growth rates than normal to 24 month old pediatrics. Reductions in length, and head circumference compared to age and sex-matched normative data, although these endelabolic acidosis during pregnancy can possible transfer of the patients with *equality* 10. Journatic calculations ( *8.11)*. Topiramate treatment that causes metabolic acidosis during pregnancy can possible transfer of topiramate to the fetus (see Warnings and Precautions ( *5.7)*, Use in Specific Populations ( *8.11)*. Manifestations of acute or chronic metabolic acidosis may include hyperventilation

# Measurement of Serum Bicarbonate in Epilepsy and Migraine Patients

Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered.

### 5.5 Suicidal Behavior and Ideation

Antiepieptic drugs (AEDs), including topiramate, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Haditve Risk 1.8, 95% (C1.2, 2.7) of suicidal approximately twice the risk (adjusted Relative Risk 1.8, 95% Ci1.2, 2.7) of suicidal thinking or behavior compared and and and and and and and and and the risk, which had a median treation among 73, 463 AED-treated patients was 0.43%, compared to 0.24% among 16.029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 placebo treated patients. There were four suicidas in drug-treated patients in the trials and none in placebo There were four suicidas in drug-treated patients in the trials and none in placebo-treated placebo treated patients and the trials and none in placebo-treated placebo treated patients in the trials and none in placebo-treated placebo treated placebo treated patients in the trials and none in placebo-treated placebo treated placebo treatebo and more placebo treatebo treatebo and more placebo treatebo treatebo treatebo and treatebo treatebo treatebo and treatebo treatebo treatebo and treatebo treatebo treatebo treatebo treatebo and treatebo treatebo treatebo and treatebo on suicide

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for an indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed

Table 4 shows absolute and relative risk by indication for all evaluated AEDs

#### Table 4: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

Indication	PlaceboPatientswithEventsper1000Patients	DrugPatientswithEventsper1000Patients	RelativeRisk:IncidenceofEventsinDrugPatients/IncidenceinPlaceboPatients	RiskDifference:AdditionalDrugPatientswithEventsper1000Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing topiramate or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epileosy and many othe suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many othe illnesses for which AEDs are prescribed are themselves associated with morbidity and mortails and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the ilness being treated.

# 5.6 Cognitive/Neuropsychiatric Adverse Reactions

Topiramate can cause cognitive/neuropsychiatric adverse reactions. The most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., confusion, psychomotor slowing, difficulty with concentration/attention, difficulties); 2) Psychiatric/behavioral disturbances (e.g., depression or mood problems); and 3) Somnolence or fatigue.

Adult Patients

#### Cognitive-Related Dysfunction

Rapid titration rate and higher initial dose were associated with higher incidences of cognitive-related dysfunction

to adult epilepsy adjunctive controlled trials, which used rapid titration (100-200 mg/day weekly increments), and target topiramate doses of 200 mg - 1000 mg/day, 56% of patients in the 800 mg/day and 1000 mg/day dose groups experienced cognitive-related dysfunction compared to approximately 42% of patients in the 200-400 mg/day groups and 14% for placebo. In this rapid titration regimen, these dose-related adverse reactions begon in the thration or in the maintenance phase, and in some patients these events began during titration and persisted into the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognRive-related adverse reactions was 19% for topiramate 50 mg/day and 26% for 400 mg/day.

The 6-month controlled trials for the preventive treatment of migraine, which used a slower titration regimen (25 mg/day weekly increments), the proportion of patients who experienced one or more contikev-related adverse reactions was 19% of to topiarantee 50 mg/day, 22% for 100 mg/day (the recommended dose), 28% for 200 mg/day, and 10% for placebo. Cognitive adverse reactions most commonly developed during titration and sometimes persisted after completion of titration.

## Psychiatric/Behavioral Disturbances

Psychiatric/behavioral disturbances (e.g., depression, mood) were dose-related for both the adjunctive epilepsy and migraine populations [see Warnings and Precautions ( 5.5)]. Somnolence/Fatigue

Somnolence and fatigue were the adverse reactions most frequently reported during clinical trials of topiramate for adjunctive epilepsy. For the adjunctive epilepsy population, the incidence of fatigue, appeared dose related. For the monotherapy epilepsy population, the incidence of somnolence was dose-related. For the migrame population, the incidences of both fatigue and somnolence were dose-related and more common in the intraframon make. the titration phase

#### Pediatric Patients

In pediatric epilepsy trials (adjunctive and monotherapy), the incidence of cognitive/neuropsychiatric adverse reactions was generally lower than that observed in cognitve/neuropsychiatric adverse reactions was generally lower than that observed in adults. These reactions included psychomotors slowing, difficulty with concentration/attention, speech disorders/related speech problems, and language problems. The most frequently reported cognitive/neuropsychiatric reactions in pediatric epilepsy patients during adjunctive therapy double-bilnd studies were somnolence and fatigue. The most frequently reported cognitive/neuropsychiatric reactions in pediatric epilepsy patients in the 50 mg/day and 400 mg/day groups during the monotherapy double-bilnd study were headache, dizziness, anorexia, and somnolence.

In pediatric migraine patients, the incidence of cognitive/neuropsychiatric adverse reactions was increased in topiramate-treated patients compared to placebo.

The risk for cognitive/neuropsychiatric adverse reactions was dose-dependent, and was greatest at the highest dose (200 mp). This risk for cognitive/neuropsychiatric adverse reactions was also greater in younger patients (6 to 11 years of age) than in older patients (12 to 17 years of age). The most common cognitive/neuropsychiatric adverse reaction in these trials was difficulty with concentration/attention. Cognitive adverse reactions commonly developed during thration and sometimes persisted for various durations after completion of thration.

The Cambridge Neuropsychological Test Automated Battery (CANTAB) was administered to adolescents (12 to 17 years) to assess the effects of topiramate on cognitive function at baseline and at the end of the Study 13 *(see Clinical Studies* (14.37)). Mean change from baseline in certain CANTAB tests suggests that topiramate treatment may result in psychomotor slowing and decreased verbal fluency.

#### 5.7 Fetal Toxicity

Topiramate cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate *in uter*ohave an increased risk of major congenital malformations, including but not limited to cleft lip and/or cleft palate (oral clefts), and of being small for gestational age (SGA). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural maformations, including cranifocial defects, and reduced fetal weights occurred in offspring [see Use in Specific Populations ( 8.1)].

Occurrent in origining piece use in Specific Populations (6.17) -Consider the benefits and the risks of topiramate when administering this drug in women of childbearing potential, particularly when topiramate is considered for a condition not usually associated with permanent injury or death [see Use in Specific Populations (8.1), Patient Courseling Information (17)]. Topiramate should be used during pregnancy, only if the potential benefit outweighs the potential risk. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Ponulations (8.1). Populations (8.1)]

# 5.8 Withdrawal of Antiepileptic Drugs

In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including topiramate, should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency (see *Clinical Studies* (141). In Stuatons where rapid withdrawal of topiramate is medically required, appropriate monitoring is recommended.

#### 5.9 Decrease in Bone Mineral Density

5.9 Decrease in Bone Mineral Density Results of a one-year active-controlled study in pediatric patients (N=63) demonstrated negative effects of topiramate monotherapy on bone mineral acquisition via statistically significant decreases in bone mineral density (BMD) measured in lumbar spine and in total body less head (see Use in Specific Populations (8.4)). Twenty-one percent of topiramate-treated in Specific Populations (8.4). Twenty-one percent of topiramate-treated in Statistical activation and the specific Population with topiramate-treated with decreased activity of the specific Population and the specific Population (8.4), specific activation was correlated with decreased serum bizatronate, which commonly difficuted. 5.4). Although is mail decreases in some markers of bone metabolism (e.g., serum alkaline phosphatase, cakium, phosphorus, and 1,25-dhydroxyvitamin D) occurred in topiramate-treated patients, more significant decreases in serum parathyroid hormone and 25-hydroxyvitamin D, hormones involved in bone metabolism, were observed, along with a hircreased excretion of urinary cakium

#### 5.10 Negative Effects on the Growth (Height and Weight)

5.10 megative Effects on the Growth (Height and Weight) Results of a one-year active-controlled study of pediatric patients (N=63) demonstrated negative effects of topiramate monotherapy on growth (i.e., height and weight) [see Use in Specific Populations (8.4)]. Although continued growth was observed in both treatment groups, the topiramate group showed statisticadly significant reductions in mean annual change from baseline in body weight compared to the control group. A smilar trend of attenuation in height velocity and height change from baseline was also observed in the topiramate group compared to the control group. Negative effects on weight and height were seen across all topiramate age subgroups. Growth (height and weight) of children receiving prolonged topiramate therapy should be carefuly monitored

#### 5.11 Serious Skin Reactions

Serious skin reactions (Stevens-Johnson Syndrome [SJS] and Toxic Epidermal Necrolysis [TEN]) have been reported in patients receiving topiramate. Topiramate should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. Inform patients about the signs of serious skin reactions.

# 5.12 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid Use)

Topiramate treatment can cause hyperammonemia with or without encephalopathy (see Adverse Reactions (6.2)). The risk for hyperammonemia with topiramate appears dose-related. Hyperammonemia has been reported more frequently when topiramate is used concomitantly with valproic acid. Postmarketing cases of hyperammonemia with or without encephalopathy have been reported with topiramate and valproic acid in patients who previously tolerated either drug alone [see Drug Interactions (7.1)].

Clinical symptoms of hyperammonemic encephalopathy often include acute alterations level of consciousness and/or cognitive function with lethargy and/or vomiting. In most cases, hyperammonemic encephalopathy abated with discontinuation of treatment.

The incidence of hyperanmonemia in pediatric patients 12 to 17 years of age in the preventive treatement of migraine trials was 26% in patients taking topiramate monotherapy at 100 mg/day, and 14% in patients taking poiramate at 50 mg/day, compared to 9% in patients taking placebo. There was also an increased incidence of markedly increased hyperanmonemia at the 100 mg dose.

Dose-related hyperammonemia was also seen in pediatric patients 1 to 24 months of age treated with topiramate and concomitant valproic acid for partial-onset epilepsy a . and this was not due to a pharmacokinetic interaction.

In some patients, hyperammonemia can be asymptomatic.

## Monitoring for Hyperammonemia

Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may Faceta minimum relations of microsoft metabolism of recent input encoded and external activity may be at an increased risk for hyperammonemia with or without encephalopathy. Although not studied, topiramate treatment or an interaction of concomtant topiramate and vapirocia calif treatment may exacerbate existing defects or unmask deficiencies in susceptible persons.

In patients who develop unexplained lethargy, vomiting or changes in mental status associated with any topiramate treatment, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.

#### 5.13 Kidney Stones

Topkramate increases the risk of kidney stones. During adjunctive epilepsy triak, the risk for kidney stones in topkramate-treated adults was 1.5%, an incidence about 2 to 4 times greater than expected in a similar, untreated oppulation. As in the general population, the incidence of stone formation among topkramate-treated patients was higher in men. Kidney stones have also been reported in peliatric patients taking topkramate for epilepsy or migraine. During long-term (up to 1 year) topkramate treatment in an open-kable extension study of 248 pediatric patients is a nonter and an open-kable extension study of 248 pediatric patients is not approved for treatment of epilepsy in pediatric patients less than 2 years old (*see Use in Specific Populations ( 8.4)*).

Topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors can promote topprimation by reducing urinary chrate excretion and by increasing urinary pH (see Warnings and Precautions (5.4)). The concomitant use of topiramate with any other drug producing metabolic actions, or potentially in patients on a ketogenic cliet, may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided.

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce ne stone formation.

An increase in urinary calcium and a marked decrease in urinary citrate was observed in topramate-treated pediatric patients in a one-year active-controlled study [see Use in Specific Populations ( 8.4)]. This increased ratio of urinary calcium/citrate increases the risk of kiltney stones and/or nephrocalcinosis.

#### 5.14 Hypothermia with Concomitant Valproic Acid Use

5.14 Hypothermia with Concomitant Vaproic Acid Use Hypothermia, defined as a drop in body core temperature to <35°C (95°F), has been reported in association with topiramate use with concomitant valproic acid both in conjunction with hyperarmonemia and in the absence of hyperarmonemia. This adverse reaction in patients using concomitant topiramate and valproate can occur after starting topiramate treatment or after increasing the daily dose of topiramate [see Drug Interactions (7.1)]. Consideration should be given to stopping topiramate or valproate in patients who develop hypothermia, which may be manifested by a variety of clinical abnormalities including lethargy, confusion, coma, and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood ammonia levels.

### 6 ADVERSE REACTIONS

6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in more detail in other sections of the baleling:
Acute Myopia and Secondary Angle Closure Glaucoma [see Warnings and Precautions (5.2)]
Visual Field Defects [see Warnings and Precautions (5.2)]
Olgophidrosis and Hyperthermia [see Warnings and Precautions (5.3)]
Metabolic Acidosis [see Warnings and Precautions (5.3)]
Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)]
Cognitive/Neuropsychiatric Adverse Reactions [see Warnings and Precautions (5.6)]
Decrease of Bone Mineral Density [see Warnings and Precautions (5.9)]
Negative Effects on Growth (Height and Weight) [see Warnings and Precautions (5.5)]
Serious Skin Reactions [see Warnings (5.1)]

- 5.10) Serious Skin Reactions [see Warnings and Precautions (5.11)] Hyperammonemia and Encephalopathy (Without and With Concomitant Val (VPA) Use) [see Warnings and Precautions (5.12)] Kidney Stones [see Warnings and Precautions (5.13)] Hypothermia with Concomitant Valproic Acid (VPA) Use [see Warnings and Precautions (5.14)] ncomitant Valoroic Acid

The data described in the following sections were obtained using topiramate tablets

# 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared the incidence of adverse reactions in the clinical trials of another drug, and may not ed to reflect the incidence of adverse reactions observed in practice

Monotherapy Epilepsy

Adults 16 Years of Age and Older

The most common adverse reactions in the controlled clinical trial (Study 1) that occurred in adults in the 400 mg/day topiramate group and at an incidence higher ( $\geq$ 10 %) than in the 50 mg/day group were: paresthesia, weight loss and anorexia (see Table 5).

Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in Study 1 discontinued therapy due to adverse reactions. The most common (\_22% more frequent than low-dose 50 mg/day topiramate) adverse reactions causing discontinuation were difficulty with memory, fatigue, asthenia, insomnia, somonolence, and paresthesia.

### Pediatric Patients 6 to 15 Years of Age

The most common adverse reactions in the controlled clinical trial (Study 1) that occurred in pediatric patients in the 400 mg/day topiramate group and at an incidenc higher ( ≥10%) than in the 50 mg/day group were fever and weight loss (see Table 5

Approximately 14% of the 77 pediatric patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. The most common (>27% more frequent than low-does 50 mg/day topiramate) adverse reactions resulting in discontinuation were difficulty with concentration/latention, fever, flushing, and confusion.

Table 5 presents the incidence of adverse reactions occurring in at least 3% of adult and pediatric patients treated with 400 mg/day topiramate and occurring with greater incidence than 50 mg/day topiramate.

# Table 5: Adverse Reactions in the High Dose Group As Compared to the Low Dose Group, in Monotherapy Epilepsy Trial (Study 1) in Adult and Pediatric Patients

Patients				
		Age	Group	
	Pediatric		Adult	
	(6 to 15	Years)	(Age :	≥ 16 Years)
		ate Daily D	osage (	Group
	(mg/day			
	50	400	50	400
Body System	(N=74)	(N=77)		60) (N=159)
Adverse Reaction	%	%	%	%
Body as a Whole - General Disorders				
Asthenia	0	3	4	6
Fever	1	12		
Leg pain			2	3
Central & Peripheral Nervous System	Disorders			
Paresthesia	3	12	21	40
Dizziness			13	14
Ataxia			3	4
Hypoesthesia			4	5
Hypertonia			0	3
Involuntary muscle contractions	0	3		
Vertigo	0	3		
Gastro-Intestinal System Disorders				
Constipation			1	4
Diarrhea	8	9		
Gastritis			0	3
Dry mouth			1	3 3
Liver and Biliary System Disorders				
Increase in Gamma-GT			1	3
Metabolic and Nutritional Disorders				

Weight loss	7	17	6	17
Platelet, Bleeding & Clotting Disorders				
Epistaxis	0	4		
Psychiatric Disorders				
Anorexia			4	14
Anxiety			4	6
Cognitive problems	1	6	1	4
Confusion	0	3		
Depression	0	3	7	9
Difficulty with concentration or attention	7	10	7	8
Difficulty with memory	1	3	6	11
Insomnia			8	9
Decrease in libido			0	3
Mood problems	1	8	2	5
Personality disorder (behavior problems)	0	3		
Psychomotor slowing			3	5
Somnolence			10	15
Red Blood Cell Disorders				
Anemia	1	3		
Reproductive Disorders, Female				
Intermenstrual bleeding	0	3		
Vaginal hemorrhage			0	3
Resistance Mechanism Disorders				
Infection	3	8	2	3
Viral infection	3	6	6	8
Respiratory System Disorders				
Bronchitis	1	5	3	4
Upper respiratory tract infection	16	18	-	
Rhinitis	5	6	2	4
Sinusitis	1	4		
Skin and Appendages Disorders				
Alopecia	1	4	3	4
Pruritus			1	4
Bash	3	4	1	4
Acne			2	3
Special Senses Other, Disorders			-	-
Taste perversion			3	5
Urinary System Disorders				
Cystitis			1	3
Micturition frequency	0	3	-	-
Renal calculus		-	0	3
Urinary incontinence	1	3	2	-
Vascular (Extracardiac) Disorders	-	-		
Flushing	0	5		
- asing		2		

## Adjunctive Therapy Epilepsy

Adults 16 Years of Age and Older

Adurts to rears or Age and Uder In pooled controlled clinical trials in adults with partial-onset seizures, primary generalized tonic-clonic seizures, or Lennox-Gastaut syndrome, 183 patients received adjunctive therapy with topiramate at dosages of 200 to 400 mg/day (recommended dosage range) and 291 patients received placebo. Patients in these trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to topiramate or placebo.

The most common adverse reactions in the controlled clinical trial that occurred in adult patients in the 200-400 mg/day topiramate group with an incidence higher (± 10%) than in the placebog group were dizenses, speech disorders/related speech problems, somnolence, nervousness, psychomotor slowing, and vision abnormal (Table 6).

somnoence, nervousness, psychomotor sowing, and vision abnormal (lable b). Table 6 presents the incidence of adverse reactions occurring in at least 3% of adult patients treated with 200 to 400 mg/day topiramate and was greater than placebo incidence. The incidence of some adverse reactions (e.g., fatigue, dizziness, paresthesia, language problems, psychomotor slowing, depression, difficulty with concentrationAttention, mood problems) was dose-related and much greater at higher than recommended topiramate dosing (i.e., 600 mg - 1000 mg daily) compared to the incidence of these adverse reactions at the recommended dosing (200 mg to 400 mg daily) range.

# Table 6: Most Common Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Epilepsy Trials in Adults <sup>a</sup>

Adjunctive Epilep	sy mais in Addics	
Body System	Placebo	Topiramate Dosage (mg/day) 200-400
Adverse Reaction	(N=291)	(N=183)
Body as a Whole-General Disorders		
Fatigue	13	15
Asthenia	1	6
Back pain	4	5
Chest pain	3	4
Influenza-like symptoms	2	3
Central & Peripheral Nervous System	Disorders	
Dizziness	15	25
Ataxia	7	16
Speech disorders/Related speech problems	2	13
Paresthesia	4	11
Nystagmus	7	10
Tremor	6	9
Language problems	1	6
Coordination abnormal	2	4
Gait abnormal	1	3
Gastro-Intestinal System Disorders		
Nausea	8	10
Dyspepsia	6	7
Abdominal pain	4	6
Constipation	2	4
Metabolic and Nutritional Disorders		
Weight loss	3	9
Psychiatric Disorders	5	5
Somnolence	12	29
Nervousness	6	16
Psychomotor slowing	2	13
Difficulty with memory	3	12
Confusion	5	11
Anorexia	4	10
Difficulty with concentration/attention	2	6
Mood problems	2	4
Agitation	2	3
Aggressive reaction	2	3
Emotional lability	1	3
Cognitive problems	1	3
Reproductive Disorders	-	5
Breast pain	2	4
Respiratory System Disorders	2	-
Rhinitis	6	7
Pharyngitis	2	6
Sinusitis	4	5
Vision Disorders	4	2
Vision abnormal	2	13
Diplopia	2	13
	5	10

Papatients in these adjunctive trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to topiramate or placebo.

In controlled clinical trials in adults, 11% of patients receiving topiramate 200 to 400 mg/day as adjunctive therapy discontinued due to adverse reactions. This rate appeared to increase at dosages above 400 mg/day. Adverse reactions associated with discontinuing topiramate included somnolence, dizziness, anxiety, difficulty with concentration or attention, fatigue and paresthesia.

Pediatric Patients 2 to 15 Years of Age

In pooled, controlled clinical trials in pediatric patients (2 to 15 years of age) with partialonset seizures, primary generalized tonic-choic seizures, or Lennox-Gastaut syndrome, 98 patients received adjunctive therapy with topiramate at dosages of 5 to 9 mg/kg/day (recommended dose range) and 101 patients received placebo.

The most common adverse reactions in the controlled clinical trial that occurred in pediatric patients in the 5 mg to 9 mg/kg/day topiramate group with an incidence higher (≥ 10 %) than in the placebo group were: fatigue and somnolence (Table 7). Table 7 presents the incidence of adverse reactions that occurred in at least 3% of

pediatric patients 2 to 15 years of age receiving 5 mg to 9 mg/kg/day (recommended dose range) of topiramate and was greater than placebo incidence.

# Table 7: Adverse Reactions in Pooled Placebo-Controlled, Adjunctive Epilepsy Trials in Pediatric Patients 2 to 15 Years of Age <sup>a,b</sup>

	Blass ba	-	
Body System/	Placebo (N=101)	Topiramate (N=98)	
Adverse Reaction	(N=101) %	(N-50) %	
Body as a Whole - General Disorder		<i>,</i> ,,	
Fatigue	5	16	
Injury	13	14	
Central & Peripheral Nervous Syste		14	
Gait abnormal	5	8	
Ataxia	2	6	
Hyperkinesia	4	5	
Dizziness	2	4	
Speech disorders/Related speech	2	4	
problems	2	-	
Gastro-Intestinal System Disorders			
Nausea	5	6	
Saliva increased	4	6	
Constipation	4	5	
Gastroenteritis	2	3	
Metabolic and Nutritional Disorders	-	-	
Weight loss	1	9	
Platelet, Bleeding, & Clotting Disord	ers		
Purpura	4	8	
Epistaxis	1	4	
Psychiatric Disorders			
Somnolence	16	26	
Anorexia	15	24	
Nervousness	7	14	
Personality disorder (behavior problems)	9	11	
Difficulty with concentration/attention	2	10	
Aggressive reaction	4	9	
Insomnia	7	8	
Difficulty with memory	0	5	
Confusion	3	4	
Psychomotor slowing	2	3	
Resistance Mechanism Disorders			
Infection viral	3	7	
Respiratory System Disorders			
Pneumonia	1	5	
Skin and Appendages Disorders			
Skin disorder	2	3	
Urinary System Disorders			
Urinary incontinence	2	4	

 Urinary incontinence
 2
 4

 <sup>a</sup> Patients in these adjunctive trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to topiramate or placebo.
 <sup>b</sup> Values represent the percentage of patients reporting a given adverse reaction.

 <sup>b</sup> Values represent the percentage of patients reporting a given adverse reaction during the study and can be included in more than one adverse reaction during the study and can be included in more than one adverse reaction.

None of the pediatric patients who received topiramate adjunctive therapy at 5 to 9 mg/kg/day in controlled clinical trials discontinued due to adverse reactions. Migraine

#### Adults

In the four multicenter, randomized, double-blind, placebo-controlled, parallel group migraine clinical trials for the preventive treatment of migraine (which included 35 pediatric patients 12 to 15 years of age), most adverse reactions occurred more frequently during the titration period than during the maintenance period.

frequently during the thration period than during the maintenance period. The most common adverse reactions with topiramate 100 mg in the clinical trials for the preventive treatment of migraine of predominanity adults that were seen at an incidence higher (± 5 %) than in the placebo group were; parsthesia, anorexia, weight loss, taste perversion, diarrhea, difficulty with memory, hypoesthesia, and nausea (see Table 8). Table 8 includes those adverse reactions that occurred in the placebo-controlled trials where the incidence in any topiramate treatment group was at least 3% and was greater than that for placebo patients. The incidence of some adverse reactions (e.g., fatigue, dizziness, somolence, difficulty with memory, difficulty with concentration/attention) was dose-related and greater at higher than recommended topiramate dosing (200 mg daily) comgared to the incidence of these adverse reactions at the recommended dosing (100 mg daily).

# Table 8: Adverse Reactions in Pooled, Placebo-Controlled, Migraine Trials in Adults <sup>a,b</sup>

Triais in Adults 4,5				
Body System/	Placebo	Topiramate Dosag	e (mg/day)	
Adverse Reaction	(N=445)	50	100	
	%	(N=235)	(N=386)	
		%	%	
Body as a Whole-Gene	ral Disorders			
Fatigue	11	14	15	
Injury	7	9	6	
Central & Peripheral N	ervous Syste	m Disorders		
Paresthesia	6	35	51	
Dizziness	10	8	9	
Hypoesthesia	2	6	7	
Language problems	2	7	6	
Gastro-Intestinal Syste	em Disorders			
Nausea	8	9	13	
Diarrhea	4	9	11	
Abdominal pain	5	6	6	
Dyspepsia	3	4	5	
Dry mouth	2	2	3	
Gastroenteritis	1	3	3	
Metabolic and Nutrition	nal Disorders			
Weight loss	1	6	9	
Musculoskeletal Syste	m Disorders	-	-	
Arthralgia	2	7	3	
Psychiatric Disorders	-		-	
Anorexia	6	9	15	
Somnolence	5	8	7	
Difficulty with memory	2	7	7	
Insomnia	5	6	7	
Difficulty with	2	3	6	
concentration/attention	2	5	0	
Mood problems	2	3	6	
Anxiety	3	4	5	
Depression	4	3	4	
Nervousness	2	4	4	
Confusion	2	2	3	
Psychomotor slowing	1	3	2	
Reproductive Disorder		5	2	
Menstrual disorder	2	3	2	
Reproductive Disorder		5	2	
Ejaculation premature	0	3	0	
Resistance Mechanism		5	0	
Viral infection	3	4	4	
Respiratory System Di		-	4	
Upper respiratory tract	12	13	14	
infection	12	13	14	
Sinusitis	6	10	6	
Pharyngitis	4	5	6	
Coughing	2	2	4	
Bronchitis	2	2	3	
Dyspnea	2	1	3	
	-	-	5	
Skin and Appendages Disorders Pruritis 2 4 2				
Special Sense Other, D	2 Sordors	4	4	
special sense Other, L	soluers			

Taste perversion	1	15	8
Urinary System Diso	rders		
Urinary tract infection	2	4	2
Vision Disorders			
Blurred vision <sup>c</sup>	2	4	2

- Burred vision f
   2
   4
   2

   Includes 35 adolescent patients age 12 to 15 years.
   •
   Values represent the percentage of patients reporting a given adverse reaction.

   • Values represent the network than one adverse reaction during the study and can be included in more than one adverse reaction category.
   •

   • Burder kilon was the most common term considered as vision abnormal. Burred vision was an included term that accounted for >50% of reactions coded as vision abnormal.
   •

Of the 1,135 patients exposed to topiramate in the adult placebo-controlled studies, 25% of topiramate-treated patients discontinued due to adverse reactions, compared to 10% of the 445 placebo-treated patients. The adverse reactions associated with discontinuing therapy in the topiramate-treated patients included paresthesia (7%), fatigue (4%), nausea (4%), difficulty with concentration/attention (3%), insomnia (3%), anorexia (2%), and dizziness (2%).

Patients treated with topiramate experienced mean percent reductions in body weight that were dose-dependent. This change was not seen in the placebo group. Mean changes of 0%, -2%, -3%, and -4% were seen for the placebo group, topiramate 50, 100, and 200 mg groups, respectively.

#### Pediatric Patients 12 to 17 Years of Age

In five, randomized, double-blind, placebo-controlled, parallel group clinical trials for the preventive treatment of migraine, most adverse reactions occurred more frequently during the thration period than during the maintenance period. Among adverse reactions with onset during titration, approximately half persisted into the maintenance period.

period. In four, fixed-doss, double-blind clinical trials for the preventive treatment of migraine in four, fixed-doss, double-blind clinical trials for the preventive treatment of migraine in the placeho group were paresthesia upper respiratory tract infection, approximation abdominal part (see Table 9). Table 9 shows adverse reactions from the pediatric trial abdominal part (see Table 9). Table 9 shows adverse reactions from the pediatric trial (Study 13 (see Clinical Studies (14.3)) in which 103 pediatric patients were treated with placeho or 50 mg or 100 mg of topiramate, and three predention trials in which 49 pediatric patients (12 to 17 years of age) were treated with placeho or 50 mg, 100 mg or 200 mg or topiramet. Table 9 also shows adverse reactions in pediatric patients in the controlled migraine trials when the incidence of na topiramate dose group was at least 5 % or higher and greater than the incidence of natione, and verse reactions (e.g., allery), fatugue, headache, anorexia, isommis, sommolence, and viral infection) was dose-related and greater at higher than recommended topiramate dosing (200 mg daily) compared to the incidence of these adverse reactions (e.g. allery), fatugue, headache, anorexia, isommis, sommolence, and viral (200 mg daily) compared to the incidence of these adverse reactions at the recommended dosing (100 mg daily).

# Table 9: Adverse Reactions in Pooled Double-Blind Studies for the Preventive Treatment of Migraine in Pediatric Patients 12 to 17 Years of Age <sup>a, b, c</sup>

Years of Age ", b, c						
Body System/	Placebo	Topiramate Dosage				
Adverse Reaction	(N=45)	50 mg/day	100 mg/day			
	%	(N=46)	(N=48)			
		%	%			
Body as a Whole - General Disorders						
Fatigue	7	7	8			
Fever	2	4	6			
Central & Peripheral N	ervous System	Disorders				
Paresthesia	7	20	19			
Dizziness	4	4	6			
Gastrointestinal Syste	m Disorders					
Abdominal pain	9	7	15			
Nausea	4	4	8			
Metabolic and Nutritio	nal Disorders					
Weight loss	2	7	4			
Psychiatric Disorders						
Anorexia	4	9	10			
Somnolence	2	2	6			
Insomnia	2	9	2			
Resistance Mechanism	n Disorders					
Infection viral	4	4	8			
Respiratory System Di	sorders					
Upper respiratory tract	11	26	23			
infection						
Rhinitis	2	7	6			
Sinusitis	2	9	4			
Coughing	0	7	2			
Special Senses Other,						
Taste perversion	2	2	6			
Vision Disorders						
Conjunctivitis	4	7	4			
82E adalassant patients age	d 12 to x16 upper	uara also included i	n advanta reaction			

<sup>a</sup>35 adolescent patients aged 12 to <16 years were also included in adverse reaction assessment for adults (Tables 11 and 12)

assessment for adults (Tables 11 and 12)  $^{b}$  Incidence is based on the number of subjects experiencing at least 1 adverse event, not the number of events.  $^{c}$  Included studies MIG-3006, MIGR-001, MIGR-002 and MIGR-003

In the double-bind placebo-controlled studies, adverse reactions led to discontinuation of treatment in 8% of placebo patients compared with 6% of topiramate-treated patients. Adverse reactions associated with discontinuing therapy that occurred in more than one topiramate-treated patient were fatigue (1%), headache (1%), and somnolence (1%).

#### Increased Risk for Bleeding

Topramate is associated with an increased risk for bleeding. In a pooled analysis of placebo-controlled studies of approved and unapproved indications, bleeding was more frequently reported as an adverse reaction for topiramate than for placebo (4.5% versus 3.0% in adult patients, and 4.4% versus 2.3% in pediatric patients). In this analysis, the incidence of serious bleeding events for topiramate and placebo was 0.3% versus 0.2% for adult patients, and 0.4% versus 0% for pediatric patients.

Versus of 2 in the autor patients, and 0-4 in the spin on the patient is Adverse bieleding reactions reported with topic varianter ranged frammatile depistaxis, ecchymosis, and increased menstrual bleeding to life-threatening hemorrhages. In patients with serious bleeding events, conditions that increased the risk for bleeding were often present, or patients were often taking drugs that cause thrombocytopenia (other antise)etic drugs) or affect platelet function or coagulation (e.g., aspirin, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, or warfarin or other anticoagulants).

### Other Adverse Reactions Observed During Clinical Trials

Other adverse reactions seen during clinical trials were: abnormal coordination, eosinophila, gingival bleeding, hematuria, hypotension, myalgia, myopia, postural hypotension, scotoma, suicide attempt, syncope, and visual field defect.

# Laboratory Test Abnormalities

Adult Patients

In addition to changes in serum bicarbonate (i.e., metabolic acidosis), sodium chloride and ammonia, topiramate was associated with changes in several clinical laboratory analytes in randomized, double-bilnd, placebo-controlled studies (*See Warnings and Precautions* (*5.4*, *5.10)*). Controlled trials of adjunctive topiramate treatment of adults for partial-onset seizures showed an increased incidence of markedly decreased serum phosphorus (6% topiramate versus 2% placebo), markedly increased serum alkalne phosphorus (6% topiramate versus 1% placebo), and decreased serum platasium (0.4 % topiramate versus 0.1 % placebo).

# Pediatric Patients

In pediatric patients (1-24 months) receiving adjunctive topiramate for partial-onset seizures, there was an increased incidence for an increased result (relative to normal analyte reference range) associated with topiramate (vs placebo) for the following clinical laboratory analytes: creatine, BUN, akaline phosphatase, and total protein, The incidence was also increased for a decreased result for bicarbonate (i.e., metabolic acidosis), and potassium with topiramate (vs placebo) [see Use in Specific Populations ( 84)]. Topiramate is not indicated for partial-onset seizures in pediatric patients less than 2 years of age.

2 yeas or lage: In pediatric patients (ranging from 6-17 years of age) receiving topiramate for the preventive treatment of migraine, there was an increased incidence for an increased result (relative to normal analyte reference range) associated with topiramate (vs placeho) for the following clinical laboratory nalytes: creatinine, BUN, uric acid, chloride, ammonia, alkaline phosphatase, total protein, platelets, and eosinophils, The incidence was also increased for a decreased result for phosphorus, bicarbonate, total white blood count, and neutrophils (see Use in Specific Populations ( 8.4)). Topiramate is not

indicated for the preventive treatment of migraine in pediatric patients less than 12 years of age.

#### 6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of topiramate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole-General Disorders: oligohydrosis and hyperthermia (see Warnings and Precautions ( 5.3)), hyperammonemia, hyperammonemic encephalopathy (see Warnings and Precautions ( 5.12)), hypothermia with concomitant valproic acid (see Warnings and Precautions ( 5.14))

Gastrointestinal System Disorders: hepatic failure (including fatalities), hepatitis, pancreatitis

Skin and Appendage Disorders: bullous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) [see Warnings and Precautions ( 5.11)], pemphigus

<u>Urinary System Disorders</u>: kidney stones, nephrocalcinosis [see Warnings and Precautions ( 5.4, 5.13)]

 $\underline{Vision\ Disorders}:$  acute myopia, secondary angle closure glaucoma [see Warnings and Precautions ( 5.1)] , maculopathy

Hematological Disorders: decrease of the International Normalized Ratio (INR) or prothrombin time when given concomitantly with vitamin K antagonist anticoagulant medications such as warfarin.

#### 7 DRUG INTERACTIONS

#### 7.1 Antiepileptic Drugs

Concomitant administration of phenytoin or carbamazepine with topiramate resulted in a clinically significant decrease in plasma concentrations of topiramate when compared to topiramate given alone. A dosage adjustment may be needed [see Dosage and Administration ( 2.1), Clinical Pharmacology ( 12.3)].

Concomitant administration of valproic acid and topiramate has been associated with hypothermia and hyperammonemia with and without encephalopathy. Examine blood ammonia levels in patients in whom the onset of hypothermia has been peorted (see Warnings and Precautions (5.12, 5.14), (linical Pharmacology (12.3)].

#### 7.2 Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, patients given topiramate concomitantly with another carbonic anhydrase inhibitor should be monitored particularly closely for the appearance or worsening of metabolic acidosis (see Clinical Pharmacology (12.3)).

#### 7.3 CNS Depressants

Concomitant administration of topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants.

### 7.4 Contraceptives

The possibility of decreased contraceptive efficacy and increased breakthrough bleeding may occur in patients taking contraceptive products with topiramate. Patients taking estrogen-containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)].

#### 7.5 Hydrochlorothiazide (HCTZ)

Topiramate C  $_{max}$  and AUC increased when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate may require a decrease in the topiramate dose [see Clinical Pharmacology (12.3)].

#### 7.6 Pioglitazone

A decrease in the exposure of pioglitazone and its active metabolites were noted with the concurrent use of pioglitazone and topiramate in a clinical rial. The clinical relevance of these observations is unknown; however, when topiramate is added to pioglitazone therapy or pioglitazone is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state [see Clinical Pharmacology (12.3)].

# 7.7 Lithium

An increase in systemic exposure of lithium following topiramate doses of up to 600 mg/day can occur. Lithium levels should be monitored when co-administered with highdose topiramate [see Clinical Pharmacology (12.3)].

#### 7.8 Amitriptyline

Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients (clinical response and not on the basis of plasma levels (see *Clinical Pharmacology( 12.3)*).

#### 8 USE IN SPECIFIC POPULATIONS

# 8.1 Pregnancy

## Pregnancy Exposure Registry

Treating reaction reactions and the registry that monitors pregnancy outcomes in women exposed to topiramate during pregnancy. Patients should be encouraged to enrol in the North American Antiepieptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepieptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at http://www.aedpregnancyregistry.org/.

### Risk Summary

Task adminiar J. Topiramate can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate in utero have an increased risk of major congenital maformations, including but not limited to cleft lip and/or cleft palate (oral clefts), and of being small for gestational age (SGA) [see Human Data]. SGA has been observed at all dosse and appears to be dose-dependent. The prevalence of SGA is greater in infants of women

#### In multiple animal species, topiramate produced developmental toxicity, including increased incidences of fetal mafformations, in the absence of maternal toxicity at clinically relevant doses (see Animal Data).

All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

# Clinical Considerations

Fetal/Neonatal Adverse Reactions

Consider the benefits and risks of topiramate when prescribing this drug to women of childbearing potential, particularly when topiramate is considered for a condition not usually associated with permanent injury or death. Because of the risk of oral clefts to the fetus, which occur in the first trimester of pregnancy, all women of childbearing potential should be informed of the potential risk to the fetus from exposure to topiramate. Women who are planning a pregnancy should be counseled regarding the relative risks and benefits of topiramate use during pregnancy, and alternative therapeutic options should be considered for these patients.

#### Labor or Delivery

Although the effect of topiramate on labor and delivery in humans has not been established, the development of topiramate-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus' ability to tolerate labor.

and/or in the recus magnet affect the recus addity to tole ace halow. Topiramate tablest treatment can cause methabolic acidosis [see Warnings and Precautions ( 5.4)]. The effect of topiramate-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus' ability to tolerate labor. Pregnant patients should be monitored for metabolic acidosis and treated as in the nonpregnant state. *[See Warnings and Precautions ( 5.4)]*. Newborns of mothers treated with topiramate tablets should be

monitored for metabolic acidosis because of transfer of topiramate to the fetus and possible occurrence of transient metabolic acidosis following birth.

Based on limited information, topiramate has also been associated with pre-term labor and premature delivery

# Data

Human Data

Human Data Data from pregnancy registries indicate an increased risk of major congenital malformations, including but not limited to oral clefts in infants exposed to topiramate during the first trimester of pregnancy. Other than oral clefts, no specific pattern of major congenital malformations or grouping of major congenital malformation types were observed. In the NAAED pregnancy registry, when topiramate-exposed infants with only oral clefts were excluded, the prevalence of major congenital malformations (4.1%) was higher than that in infants exposed to a reference AED (1.8%) or in infants with mothers without epilepsy and without exposure to AEDs (1.1%). The prevalence of oral clefts among topiramate-exposed infants (1.4%) was higher than the prevalence in infants exposed to a reference AED (0.3%) or the prevalence in infants with mothers without epilepsy and without exposure to AEDs (1.1%). It was also higher than the background prevalence in United States (0.17%) as estimated by the Centers for Disease Control and Prevention (CDC). The relative risk of oral clefts in topiramate-exposed pregnancies in the NAAED Pregnancy Registry was 12.5 (5%. Confidence Interval (CI) 5.9 - 26.37) as compared to the risk in a background population of untreated Women. The UKE pilepsy and regnancy Registry areperated psile conterval Interval (C) 5.9 - 26.3 / as Compared to the risk in a background population of untreated women. The UK Epilepsy and Pregnancy Register reported a prevalence of oral clefts among infants exposed to topiramate monotherapy (3.2%) that was 16 times higher than the background rate in the UK (0.2%).

higher than the background rate in the UK (0.2%). Data from the NAAED pregnancy registry and a population-based birth registry cohort indicate that exposure to topiramate *in uterois* associated with an increased risk of SGA newborns (birth weight <10th percentile). In the NAAED pregnancy registry, 19.7% of topiramate-exposed newborns were SGA compared to 7.9% of newborns exposed to a reference AED and 5.4% of newborns of mothers without epilepsy and without AED exposure. In the Medical Birth Registry of Norway (MBRN), a population-based pregnancy registry, 25% of newborns in the topiramate monotherapy exposure group were SGA compared to 9% in the comparison group newposed to AEDs. The long-term consequences of the SGA findings are not known.

#### Animal Data

When topiramate (0, 20, 100, or 500 mg/kg/day) was administered to pregnant mice during the period of organogenesis, incidences of fetal maformations (primarily crainofacial defects) were increased at all doess. Fetal body weights and skeletal ossification were reduced at the highest dose tested in conjunction with decreased maternal body weight gain. A no-effect dose for embryofetal developmental toxicity in mice was not identified. The bwest dose tested, which was associated with increased mailormations, is less than the maximum recommended human dose (MBHD) for epilepsy (400 mg/day) or migraine (100 mg/day) on a body surface area (mg/m<sup>2</sup>) basis.

epidesy (400 mg/day) of mg/ ane (200 mg/day) on a body surface area (mg/m -) basis. In pregnant rats administered topriamate (0, 20, 100, and 500 mg/kg/day) or 0, 0, 2, 2, 5 30, and 400 mg/kg/day) orally during the period of organogenesis, the frequency of limb maiformations (extrodacty), micromelia, and amelia) was increased in fetuses at 400 and 500 mg/kg/day. Embryotoxicity (reduced fetal body weights, increased incidences of structural variations) was observed at doese as how as 20 mg/kg/day. Clinical signs of maternal toxicity were seen at 400 mg/kg/day and above, and maternal body weight gain was reduced at doese of 100 mg/kg/day or greater. The no-effect does (2,5 mg/kg/day) for embryofetal developmental toxicity in rats is less than the MRHD for epidepsy or migraine on a mg/m<sup>2</sup>basis.

Impraine on a mg/m loase. In pregnant rabbits administered topiramate (0, 20, 60, and 180 mg/kg/day or 0, 10, 35, and 120 mg/kg/day) orally during organogenesis, embryofetal mortality was increased at 35 mg/kg/day, and increased incidences of fetal mafformations (primarily rib and vertebrai mafformations) were observed at 120 mg/kg/day. Evidence of maternal toxicity (decreased body weight gain, clinical signs, and/or mortality) was seen at 35 mg/kg/day and above. The no-effect dose (20 mg/kg/day) for embryofetal developmental toxicity in rabbits is equivalent to the MRHD for epilepsy and approximately 4 times the MRHD for migraine on a mg/m <sup>2</sup>basis.

When topiramate (0, 0.2, 4, 20, and 100 mg/kg/day or 0, 2, 20, and 200 mg/kg/day) was administered orally to female rats during the latter part of gestation and throughout lactation, offspring exhibited decreased vibibility and delayed physical development at 200 mg/kg/day and reductions in pre- and/or postweaning body weight gain at 2 to mg/kg/day and above. Maternal toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg/day or greater.

In a rat embryofetal development study which included postnatal assessment of offspring, oral administration of topiramate (0, 0.2, 2.5, 30, and 400 mg/kg) to pregnant animals during the period of organogenesis resulted in delayed physical development in offspring at 400 mg/kg/day and persistent reductions in body weight gain in offspring at 330 mg/kg/day and higher. The no-effect dose (0.2 mg/kg/day) for pre- and postnatal developmental toxicity in rats is less than the MRHD for epilepsy or migraine on a mg/m2 basis.

#### 8.2 Lactation

Risk Summary

Topiramate is excreted in human milk [see Data]. The effects of topiramate on milk production are unknown. Diarrhea and somnolence have been reported in breastfed infants whose mothers receive topiramate treatment.

The developmental and health benefits of breastfeeding should be considered along with

mother's clinical need for topiramate tablets and any potential adverse effects on the breastfed infant from topiramate tablets or from the underlying maternal condition.

#### Data Human Data

Limited data from 5 women with epilepsy treated with topiramate during lactation showed drug levels in milk similar to those in maternal plasma.

#### 8.3 Females and Males of Reproductive Potential

Contraception

Women of childbearing potential who are not planning a pregnancy should use effective contraception because of the risk of major congenital malformations, including oral clefts, and the risk of infants being SGA [see Drug Interactions (7.4) and Use in Specific Populations (8.1)]

#### 8.4 Pediatric Use

Adjunctive Treatment for Epilepsy

Pediatric Patients 2 Years of Age and Older

The safety and effectiveness of topiramate tablets as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome have been established in pediatric patients 2 years of age and older [see Adverse Reactions ( 6.1) and Clinical Studies ( 14.2)].

# Pediatric Patients Below the Age of 2 Years

Pediatric Patients Below the Age of 2 Years Safety and effectiveness in patients below the age of 2 years have not been established for the adjunctive therapy treatment of partial-onset secures, primary generalized tonic-clonic secures, or secures associated with Lennox-Gastaut syndrome. In a single randomized, double-blind, placebo-controlied investigational trial, the efficacy, safety, and tolerability of topiramate oral liquid and sprinkle formulations as an adjunct to concurrent antiepleiptic drug therapy in pediatric patients 1 to 24 months of age with refractory partial-onset seizures were assessed. After 20 days of double-blind treatment, topiramate (at Kied doss of 5, 15, and 25 mg/kg/day) did not demonstrate efficacy compared with placebo in controlling seizures.

nd an liatric frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications).

These very young pediatric patients appeared to experience an increased risk for infections (any topiramate dose 12%, placebo 0%) and of respiratory disorders (any topiramate dose 40%, placebo 10%). The following adverse reactions were observed at least 3% of patients on topiramate and were 3% to 7% more frequent than in patie on placebo: viral infection, bronchits, pharyngits, rhintis, ottis media, upper respiratt infection, coupd, and bronchospasm. A generally similar profile was observed in older pediatric patients [see Adverse Reactions ( 6)].

Topiramate resulted in an increased incidence of patients with increased creatinine (any topiramate dose 5%, placebo 0%), BUN (any topiramate dose 3%, placebo 0%), and protein (any topiramate dose 34%, placebo 6%), and an increased incidence of decreased potassium (any topiramate dose 7%, placebo 0%). This increased frequency of abnormal values was not dose-related. Creatinine was the only analyte showing a noteworthy increased incidence (topiramate 25 mg/kg/day 5%, placebo 0%) of a markedly abnormal increase. The significance of these findings is uncertain.

Topiramate treatment also produced a dose-related increase in the percentage of Topramate treatment also produced a dose-reated increase in the percentage of patients who had a shift from normal at baseline to high/increased (above the normal statement erange) in total eosimophic locunt at the end of treatment. The incidence of the abnormal shifts was 6 % for total eosimophic for 5 mg/kg/day, 9% for 15 mg/kg/day, 14% for 25 mg/kg/day, and 11% for any topiramate dose. There was a mean dose-related increase in alkaline phosphrates. The single findings is uncertain. Warnings and Precautions (5.12)].

Treatment with topiramate for up to 1 year was associated with reductions in Z SCORES for length, weight, and head circumference [see Warnings and Precautions ( 5.4), Adverse Reactions ( 6)] .

In open-label, uncontrolled experience, increasing impairment of adaptive behavior was documented in behavioral testing over time in this population. There was a suggestion that this effect was dose-related. However, because of the absence of an appropriate control group, it is not known if this decrement in function was treatment-related or reflects the patient's underlying disease (e.g., patients who received higher doses may have more severe underlying disease) [see Warnings and Precautions ( 5.6)].

In this open-label, uncontrolled study, the mortality was 37 deaths/1000 patient years. It is not possible to know whether this mortality rate is related to topiramate treatment, because the background mortality rate for a similar, significantly refractory, young pediatric population (1-24 months) with partial epilepsy is not known. Monotherapy Treatment Partial-Onset Epilepsy in Patients <2 Years Older

The safety and effectiveness of topiramate as monotherapy for the treatment of partial onset seizures or primary generalized tonic-clonic seizures have been established in pediatric patients aged 2 years and older [see Adverse Reactions (6.1), Clinical Studies ) решал 14.1)].

14.1)).
14.1).
A one-year, active-controlled, open-label study with blinded assessments of bone mineral density (BMD) and growth in pediatric patients 4 to 15 years of age, including 63 patients with recent or new conset of eighesy, was conducted to assess effects of topiramate (N=28, 6-15 years of age) versus levelt acetam (N=35, 4-15 years of age) monotherapy on bone mineralization and on height and weight, which reflect growth. Effects on bone mineralization were evaluated via dual-energy X-ray absorptiometry and blood markers. Table 10 summarizes effects of topiramate and the comparator were positive. Therefore, the Least Square Mean values for topiramate and the comparator were positive. Therefore, the Least Square Mean treatment differences shown reflect a topiramate-induced attenuation of the key safety outcomes. Statistically is ginificant effects were observed for decreases in BMD (and bone mineral content) in lumbar spine and total body less head and in weight. Subgroup analyses according to age demonstrated similar negative effects of al key safety outcomes (i.e., BMD, height, weight).

# Preventive Treatment of Migraine in Pediatric Patients 12 to 17 Years of Age

Preventive Treatment of Migraine in Pediatric Patients 12 to 17 Years of Age Safety and effectiveness of topiramate for the preventive treatment of migraine was studied in 5 double-bind, randomized, placebo-controlled, parallel-group trials in a total of 219 pediatric patients, at doses of 50 to 200 mg/day, or 2 to 3 mg/kg/day. These comprised a fixed dose study in 103 pediatric patients 12 to 17 years of age (see Clinical Studies (14), a flexible dose (12 to 3 mg/kg/day), placebor-controlled study in 153 pediatric patients, at otal of 50 pediatric patients 12 to 16 years of age), and a total of 49 pediatric patients 12 to 17 years of age in 3 studies for the preventive treatment of migraine primarily in adults. Open-label extension phases of 3 studies enabled evaluation of long-term safety for up to 6 months after the end of the double-blind phase.

Efficacy of topiramate for the preventive treatment of migraine in pediatric patients 12 to 17 years of age is demonstrated for a 100 mg daily dose in Study 13 *[see Clinical Studies* (14.3)). Efficacy of topiramate (2 to 3 mg/kg/day) for the preventive treatment of migraine was not demonstrated in a placebo-controlled trial of 157 pediatric patients (6 to 16 years of age) that included treatment of 67 pediatric patients (12 to 16 years of age) for 20 weeks.

In the pediatric trials (12 to 17 years of age) in which patients were randomized to placebo or a fixed daily dose of topiramate, the most common adverse reactions with topiramate that were seen at an incidence higher (±5%) than in the placebo group were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain *[see Adverse Reactions (6)]*.

The most common cognitive adverse reaction in pooled double-blind studies in pe patients 12 to 17 years of age was difficulty with concentration/attention [see Wa and Precautions ( 5.6)].

Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated pediatric migraine patients [see Warnings and Precautions (5.4)]

In topiramate-treated pediatric patients (12 to 17 years of age) compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, uric acid, chloride, ammonia, total protein, and platetest. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate (see Adverse Reactions (6-10)).

Notable changes (increases and decreases) from baseline in systolic blood pressure diastolic blood pressure, and pulse were observed occurred more commonly in pedi patients treated with topiramate compared to pediatric patients treated with placebo diatric [see Clinical Pharmacology ( 12.2)].

#### Preventive Treatment of Migraine in Pediatric Patients 6 to 11 Years of Age

Safety and effectiveness in pediatric patients below the age of 12 years have not been established for the preventive treatment of migraine.

established for the preventive treatment of migraine. In a double-blind study in 90 pediatric patients 6 to 11 years of age (including 59 topiramate-treated and 31 placebo patients), the adverse reaction profile was generally similar to that seen in pooled double-blind studies of pediatric patients 12 to 17 years of age. The most common adverse reactions that occurred in topiramate-treated pediatric patients 6 to 11 years of age, and at least twice as frequently than placebo, were gastroenterist (12% topiramate, 6% placebo), sinusits (10% topiramate, 0% placebo), weight loss (8% topiramate, 3% placebo) and paresthesia (7% topiramate, 0% placebo). Difficulty with concentration/attention occurred in 3 topiramate-treated patients (5%) and 0 placebo-treated patients.

The risk for cognitive adverse reaction was greater in younger patients (6 to 11 years of age) than in older patients (12 to 17 years of age) [see Warnings and Precautions ( 5.6)]

# Juvenile Animal Studies

When topiramate (0, 30, 90, and 300 mg/kg/day) was administered orally to rats during the µvenile period of development (postnatal days 12 to 50), bone growth plate thickness was reduced in males at the highest dose. The no-effect dose (90 mg/kg/day) for adverse developmental effects is approximately 2 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m ²) basis.

## Table 10 Summary of topiramate Tablets Treatment Difference

Results at 12 Months for Ke	y Safety Outcomes	
Safety Parameter	Treatment Difference in Least Square Means (95 % Confidence Interval)	
Annual Change in BMD Lumbar Spine (g/cm <sup>2</sup> )	-0.036 (-0.058, -0.014)	
Annual Change in BMD TBLH* (g/cm <sup>2</sup> )	-0.026 (-0.039, -0.012)	
Annual Change in Height (cm) (4-9 years, Primary Analysis Population for Height) **	-0.84 (-2.67, 0.99)	
Annual Change in Height (cm) (4-15 years)	-0.75 (-2.21, 0.71)	
Annual Change in Height (cm) (10-15 years)	-1.01 (-3.64, 1.61)	
Height Velocity (cm/year) (4-9 years)	-1.00 (-2.76, 0.76)	
Height Velocity (cm/year) (4-15 years)	-0.98 (-2.33, 0.37)	
Height Velocity (cm/year) (10-15 years)	-0.96 (-3.24, 1.32)	
Annual Change in Weight (kg) -2.05 (-3.66, -0.45)		
* TBLH=total body less head		

\* Whereas no patients were randomized to 2-5 year age subgroup for topiramate tablets, 5 patients (4-5 years) were randomized to the active control group.

Metabolic acidosis (serum bicarbonate < 20 mEq/L) was observed in all topiramate tablets-treated patients at some time in the study (see Warnings and Precautions (5.4)). Over the whole study, 76% more topiramate tablets-treated patients experienced persistent metabolic acidosis (i.e. 2 consecutive visits with or final serum bicarbonate < 20 mEq/L) compared to leverthracetam treated patients. experienced a markedly abnormally law serum bicarbonate (e. absolute value < 11 mEq/L and  $\geq 5$  mEq/L decrease from pre-treatment, indicating the frequency of more severe metabolic acidosis, compared to

levetiracetam -treated patients. The decrease in BMD at 12 months was correlated with decreased serum bicarbonate, suggesting that metabolic acidosis was at least a partial factor contributing to this adverse effect on BMD.

topramate tablets-treated patients exhibited an increased risk for developing an increased serum creatinine and an increased serum glucose above the normal reference range compared to control patients.

Pediatric Patients Below the Age of 2 Years

Safety and effectiveness in patients below the age of 2 years have not been established for the monotherapy treatment of epilepsy.

Preventive Treatment of Migraine

Pediatric Patients 12 to 17 Years of Age

Safety and effectiveness of Lopiramate for the preventive treatment of migraine was studied in 5 double-blind, randomized, placebo-controlled, paralle-group traks in a total of 219 pediatric patients, at doses of 50 to 200 mg/day, or 2 to 3 mg/kg/day. These comprised a fixed dose study in 103 pediatric patients 12 to 17 years of age [see Clinical Studies (14.3)], a factible dose [2 to 3 mg/kg/day], placebo-controlled study in 157 pediatric patients, at dexibe dose [2 to 3 mg/kg/day], placebo-controlled study in 157 age], and a total of 49 pediatric patients 12 to 17 years of age in 3 studies for the preventive treatment of migraine primarily in adults. Open-bable textension phases of 3 studies enabled evaluation of long-term safety for up to 6 months after the end of the double-blind phase. double-blind phase.

Efficacy of topiramate for the preventive treatment of migraine in pediatric patients 12 to 17 years of age is demonstrated for a 100 mg daily dose in Study 13 [see Clinical Studies (14.3)]. Efficacy of topiramate [2 to 3 mg/kg/day] for the preventive treatment of migraine was not demonstrated in a placebo-controlled trial of 157 pediatric patients (6 to 16 years of age) that included treatment of 67 pediatric patients (12 to 16 years of age) for 20 weeks.

In the pediatric trials (12 to 17 years of age) in which patients were randomized to placebo or a fixed daily dose of topiramate, the most common adverse reactions with topiramate that were seen at an incidence halper (>55%) than in the placebo group were: paresthesia, upper respiratory tract infection, anorexia, and abdominal pain *[see Adverse Reactions (6)]*.

The most common cognitive adverse reaction in pooled double-blind studies in pediatric patients 12 to 17 years of age was difficulty with concentration/attention [see Warnings and Precautions ( 5.6)].

Markedly abnormally low serum bicarbonate values indicative of metabolic acidosis were reported in topiramate-treated pediatric migraine patients [see Warnings and Precautions (5.41).

In topiramate-treated pediatric patients (12 to 17 years of age) compared to placebo-treated patients, abnormally increased results were more frequent for creatinine, BUN, unit acid, chloride, ammonia, total protein, and platelets. Abnormally decreased results were observed with topiramate vs placebo treatment for phosphorus and bicarbonate (see Adverse Reactions (6-10)).

Notable changes (increases and decreases) from baseline in systolic blood pressure, diastolic blood pressure, and pulse were observed occurred more commonly in pediatric patients treated with topiramate compared to pediatric patients treated with placebo [see Clinical Pharmacology (12.2)].

#### Pediatric Patients Below the Age of 12 Years

Safety and effectiveness in pediatric patients below the age of 12 years have not been established for the preventive treatment of migraine.

In a double-blind study in 90 pediatric patients 6 to 11 years of age (including 59 topiramate-treated and 31 placebo patients), the adverse reaction profile was generally topramate-treated and 31 placebo patients), the adverse reaction profile was generally similar to that seen in pooled double-bind studies of pediatric patients 12 to 17 years of age. The most common adverse reactions that occurred in topramate-treated pediatric patients 6 to 11 years of age, and at least twice as frequently than placebo, were gastroenteriks (12% topiramate, 6% placebo), sinusitis (10% topiramate, 3% placebo), weight loss (8% topiramate, 3% placebo) and paresthesia (7% topiramate, 0% placebo). Diffculty with concentration/attention occurred in 3 topiramate-treated patients (5%) and 0 placebo-treated patients.

The risk for cognitive adverse reaction was greater in younger patients (6 to 11 years of age) than in older patients (12 to 17 years of age) [see Warnings and Precautions (5.6)]

#### Juvenile Animal Studies

When topiramate (0, 30, 90, and 300 mg/kg/day) was administered orally to rats during the µvenile period of development (postnatal days 12 to 50), bone growth plate thickness was reduced in males at the highest dose. The no-effect dose (90 mg/kg/day) for adverse developmental effects is approximately 2 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m<sup>2</sup>) basis.

#### 8.5 Geriatric Use

In clinical trials, 3% of patients were over age 60. No age-related differences in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with age-related renal impairment (creatinine clearance rate <70 mL/min/1.73 m  $^3$ ) resulting in reduced clearance [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].

#### 8.6 Renal Impairment

The clearance of topiramate is reduced in patients with moderate (creatinine clearance 30 to 69 mL/min/1.73 m  $^2)$  and severe (creatinine clearance <30 mL/min/1.73 m  $^2)$  renal impairment. A dosage adjustment is recommended in patients with moderate or severe renal impairment [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].

### 8.7 Patients Undergoing Hemodialysis

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than in a normal individual. A dosage adjustment may be required [see Dosage and Administration (2.6), ClineAPharmacology (12.3)].

#### 10 OVERDOSAGE

Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, burred vision, dipoipia, impaired mentation, lethargy, abnormal coordination, stupor, hypotension, abdomial pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after overdoses involving topiramate.

Topiramate overdose has resulted in severe metabolic acidosis [see Warnings and Precautions ( 5.4)].


A patient who ingested a dose of topiramate between 96 and 110 g was admitted to a hospital with a coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days.

In the event of overdose, topiramate should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved. Hemodialysis is an effective means of removing topiramate from the body.

#### 11 DESCRIPTION

Topiramate is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, and 100 mg circular tablets and 200 mg capsule shaped tablets for oral administration.

tables to to an automatation. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/ml. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C  $_{12}H_{21}NO$  §5 and a molecular weight of 339.36. Topiramate is designated chemically as 2,334,5-Di-O-sopropylidene-8-D-fructopyranose sulfamate and has the following structural formula:



topiramate and has the following inactive ingredients: hypromeliose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, pregelatinized starch, sodium starch glycotale and ttahium dioxide. In addition, the 25 mg also contains FD&C Blue#2; the 50 mg and 100 mg also contain red iron oxide and yellow iron oxide; and the 200 mg also contains red iron oxide.

#### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

The precise mechanisms by which topiramate exerts its anticonvulsant and preventive The precise mechanisms by which topramate exerts is anticonvulsant and preventive migraine effects are unknown, however, preclincial studies have revealed four properties that may contribute to topiramate's efficacy for eplepsy and the preventive treatment of migraine. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.

#### 12.2 Pharmacodynamics

Topiramate has anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests. Topiramate is only weakly effective in blocking clonic seizures induced by the GABA *i*rcreptor antagonist, pentylenettrazole. Topiramate is also effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by kindling of the amygdala or by global ischemia.

or the amygdala or by global schema. Changes (increases and decreases) from baseline in vital signs (systolic blood pressure-SBP, diastolic blood pressure-DBP, pulse) occurred more frequently in pediatric patients (6 to 17 years) treated with various daily does of topiramate (50 mg, 100 mg, 200 mg, 2 to 3 mg/kg) than in patients treated with placebo in controlled trials for the preventive treatment of migraine. The most notable changes were SBP -90 mm Hg, DBP <50 mm Hg, SBP or DBP increases or decreases  $\pm 20$  mm Hg, and pulse increases or decreases  $\pm 30$  beats per minute. These changes were often dose-related, and were most frequently associated with the greatest treatment difference at the 200 mg dose level. Systematic collection of orthostatic vital signs has not been conducted. The clinical significance of these various changes in vital signs has not been clearly established.

#### 12.3 Pharmacokinetics

Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose. The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution. The bioavailability of topiramate is not affected by food.

bioavailability of topramate is not artecuted by rout. The pharmacokinetics of topiramate are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination half-life is 21 hours after single or multiple doses. Steady-state is thus reached in about 4 days in patients with normal renal function. Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration in range of 0.5 to 250 µg/mL. The fraction bound decreased as blood concentration increased.

Carbamazepine and phenytoin do not alter the binding of topiramate. Sodium valproate, at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%. Topiramate does not influence the binding of sodium valproate.

## Metabolism and Excretion

Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Six metabolites have been identifu in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is mecapones are formed via nyoroxyaton, nyoroyss, and gucuronolatón. Inere is evidence of real tubular reabsorption of topiramate. In ratus, given probenecia to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evuluated in humans. Overall, oral pisama clearance (CL/F) is approximately 20 to 30 mL/min in adults following oral administration.

# Specific Populations

### Renal Impairment

The clearance of topiramate was reduced by 42% in subjects with moderate renal impairment (creatinine clearance 30 to 69 mL/min/L.73 m<sup>-2</sup>) and by 54% in subjects with severe renal impairment (creatinine clearance <30 mL/min/L.73 m<sup>-2</sup>) compared to subjects with normal renal function (creatinine clearance >70 mL/min/L.73 m<sup>-2</sup>) (see Dosage and Administration (2.4) and (2.5)].

#### Hemodialysis

Topiramate is cleared by hemodialysis. Using a high-efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyser at 400 mL/min. This high clearance (compared to 20 to 30 mL/min total oral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodialysis treatment period [see Dosage and Administration (2.6), Use in Specific Populations (8.7)].

#### Hepatic Impairment

Plasma clearance of topiramate decreased a mean of 26% in patients with moderate to severe hepatic impairment

## Age, Gender, and Race

Age, Gender, and Race The pharmacoknetics of topiramate in elderly subjects (65 to 85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function (creatinic tekarrance 1:20%), compared to young adults. Following a single oral 100 mg dose, maximum plasma concentration for elderly and young adults. Bolowing a schleved at approximately 1 to 2 hours. Reflecting the primary renal elimination of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%, respectively, netlerly. Neduced topiramate clearance resulted in slightly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young adults. Topiramate clearance is decreased in the elderly only to the extent that renal function is reduced (*see Dosage and Administration (2.4)* and *Use in Specific Populations (8.5)*].

# Clearance of topiramate in adults was not affected by gender or race.

Pediatric Pharmacokinetics

Pharmacokinetics of topiramate were evaluated in patients age 2 to <16 years. Patients received either no or a combination of other antiepileptic drugs. A population receive enter in ord a containade of old an interpleptic drugs. A population pharmacokinetic model was been and the basis of pharmacokinetic data from relevant topiramate clinical studies. The dataset contained bediat from 1217 subjects including 258 pediatric patients age 2 to case of earlies pediatric patients <10 years of age).

agei. Pediatric patients on adjunctive treatment exhibited a higher oral clearance (L/h) of topiramate compared to patients on monotherapy, presumably because of increased clearance from concomtant enzyme-inducing antiepleiptic drugs. In comparison, topiramate clearance per kg is greater in pediatric patients than in adults and in young pediatric patients (down to 2 years) than in older pediatric patients than in adults and in young patients compared to adults and also in younger pediatric patients compared to older pediatric patients. Clearance was independent of dose.

# As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.

# Drug Interactions

In vitrostudies indicate that topiramate does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, or CYP3A4/5 isozymes, In vitrostudies indicate that topiramate is a mild inhibitor of CYP2C19 and a mild inducer of CYP3A4.

#### Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 11.

In Table 11, the second column (AEC concentration) describes what happens to the concentration of the co-administered AED listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the co-administral of a drug listed in the first column modifies the concentration of topiramate when compared to topiramate tablets given alone.

# Table 11: Summary of AED Interactions with Topiramate

AED	AED Concentration	Topiramate
Co-administered		Concentration
Phenytoin	NC or 25% increase <sup>a</sup>	48% decrease
Carbamazepine (CBZ)	NC	40% decrease
CBZ epoxide <sup>b</sup>	NC	NE
Valproic acid	11% decrease	14% decrease

Phenobarbital	NC	NE
Primidone	NC	NE
Lamotrigine	NC at TPM doses up to	13% decrease

 <sup>a</sup>= Plasma concentration increased 25% in some patients, generally to day dosing regimen of phenytoin.
 <sup>b</sup>= Is not administered but is an active metabolite of carbamazepine. ed 25% in some patients, generally those on a twice a

NC = Less than 10% change in plasma concentration AED = Antiepileptic drug. NE = Not Evaluated. TPM = Topiramate

#### Oral Contraceptives

Ural contraceptives In a pharmacokhetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), topiramate, given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significant doses a diginctive therapy in patients taking valginicants, and 30%, respectively) when given as adjunctive therapy in patients taking valginicanty affect exposure to NET and there was no significant dose-dependent change in EE exposure for Moses of 50 to 200 mg/day. The clinical significance of the changes observed is not known (see Drug Interactions (7.4)). Digoxin

In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant topiramate administration. The clinical relevance of this observation has not been established.

#### Hydrochlorothiazide

Hydrochlorothiazide A drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (HCTZ) (25 mg every 24 hours) and topframate (96 mg every 12 hours) when administered alone and concomitantly. The results of this study indicate that topframate. C<sub>max</sub>(arceased by 27% and ALC) increased by 29% when HCTZ was added to topframate. The clinical significance of this change is unknown. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topframate. Clinical laboratory results indicated decreases in serum potassium after topframate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination. Metformin

 $\label{eq:pharmacokinetics} A drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin (S00 mg every 12 hours) and topiramate in plasma when metformin was given aince and when metformin and topiramate (100 mg every hours) were given simultaneously. The results of this study indicated that the mean metformin C maxand AUC __12_Mircreased by 18% and 25%, respectively, when topiramate was added. Topiramate was added. Topiramate was added. Topiramate and the direct metformin tham. The clinical significance of the affect of topiramate was the large was added. Topiramate on metformin pharmacokinetics is not known. The final significance of the effect of metformin on topiramate pharmacokinetics is unclear.$ ery 12

## Pioglitazone

A drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topriamate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUC  $_{\tau_{1},s_{2}}$  of pioglitazone with no alteration in C  $_{maxss}$  observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C  $_{maxss}$  and AUC  $_{\tau_{1},s_{2}}$  for post of the active hydroxy-metabolite was noted as well as a 60% decrease in c  $_{maxss}$  and AUC  $_{\tau_{1},s_{2}}$  of the active hydroxy-metabolite. The clinical significance of these findings is not known.

# Glyburide

A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 22% decrease in C m<sub>max</sub>and a 25% reduction in AUC <sub>24</sub> for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolites, 4-*t* trans-hydroxy-glyburide (M1) and 3-cs<sup>2</sup>-hydroxyglyburide (M2), was also reduced by 13% and 15%, and C <sub>max</sub>was reduced by 18% and 25%, concomitant administration of glyburide.

#### Lithium

In patients, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C $_{\rm max}$ and 26% for AUC) following topiramate doses up to 600 mg/day [see Drug Interactions (7.7)]. hate

## Haloperidol

The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 males, 7 multiple d females).

#### Amitriptvline

There was a 12% increase in AUC and C  $_{\rm max}$  for amitriptyline (25 mg per day) in 18 healthy subjects (9 males, 9 females) receiving 200 mg/day of topiramate. Sumatriptan

Multiple dosing of topiramate (100 mg every 12 hours) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single-dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).

## Risperidone

When administered concomitantly with topiramate at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperdione systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/d y doses of topiramate). No alterations of 9-hydroxyrisperidone levels were observed. Co-administration of topiramate 400 mg/day with risperdone resulted in a 14% increase in the maximum 24% increase in AUC 12 to 12% increase in AUC 120 topiramate. There were no clinically significant changes in the systemic exposure of risperidone pulse 9-hydroxyrisperidone or of topiramate; therefore, this interaction is not likely to be of clinical significance.

# Propranolol

Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate, at a dose of 200 mg/day of topiramate.

# Dihydroergotamine

Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study. Diltiazem

Co-administration of dilitiazem (240 mg Cardizem CD<sup>®</sup>) with topiramate (150 mg/day) resulted in a 10% decrease in C maxand a 25% decrease in dilitiazem AUC, a 27% decrease in des-acetyl dilitiazem AUC, and no effect on N-desmethyl dilitiazem. Co-administration of topiramate with dilitiazem resulted in a 16% increase in A Cmaxanda 12% horease in AUC informate.

## Venlafaxine

Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg) did not affect the pharmacokinetics of topiramate.

# 13 NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenesis

Carcinogenesis An increase in urinary bladder tumors was observed in mice given topiramate (0, 20, 75, and 300 mg/kg/day) in the diet for 21 months. The increase in the incidence of bladder tumors in males and females receiving 300 mg/kg/day was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. The indipier of the doses not associated with an increase in tumors (75 mg/kg/day) is equivalent to the maximum recommended human dose (MRHD) for eplepsy (400 mg), and approximately 4 times the MRHD for migraine (100 mg) on a mg/m2 basis. The relevance of this finding to human carcinogenic risk s uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg/day lapproximately 3 times the MRHD for epilepsy and 12 times the MRHD for migraine on a mg/m2 basis).

#### Mutagenesis

Topiramate did not demonstrate genotoxic potential when tested in a battery of *in* vitroand *in* vivoassays. Topiramate was not mutagenic in the Ames test or the *in* vitromouse lymphoma assay; it did not increase unscheduled DNA synthess in rat hepatocytes *in* vitro; and it did not increase chromosomal aberrations in human lymphocytes *in* vitroro in rat bone marrow *in* vivo.

### Impairment of Fertility

No adverse effects on male or female fertility were observed in rats administered topramate orally at doses up to 100 mg/kg/day (2.5 times the MRHD for epilepsy and 10 times the MRHD for migraine on a mg/m <sup>2</sup>basis) prior to and during mating and early pregnancy.

14 CLINICAL STUDIES

The studies described in the following sections were conducted using topiramate tablets

# 14.1 Monotherapy Epilepsy

Patients with Partial-Onset or Primary Generalized Tonic-Clonic Seizures


Adults and Pediatric Patients 10 Years of Age and Older

The effectiveness of topiramate as initial monotherapy in adults and pediatric patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures was established in a multicenter, randomized, double-blind, parallel-group trial (Study 1).

was established in a multicenter, randomized, double-bind, parallel-group trial (Study 1). Study 1 was conducted in 487 patients diagnosed with epilepsy (6 to 83 years of age) who had 1 or 2 well-documented secures during the 3-month retrospective baseline phase who then entered the study and received topiramate 25 mg/day for 7 days in an open-label fashion. Forty-nine percent of patients had no prior AED treatment and 17% had a diagnosis of epilepsy for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior ta advination. In the double-bind phase, 470 patients were randomized to thrate up to 50 mg/day or 400 mg/day. If the target dose could not be achieved, patients were maintained on the maximum tolerated dose. Fifty-eight percent of patients achieved the maximal dose of 400 mg/day for >2 weeks, and patients who did not tolerate 150 mg/day were discontinued.

Uncontained. The primary efficacy assessment was a between-group comparison of time to first secure during the double-blind phase. Comparison of the Kaplan-Meier survival curves of time to first secure favored the topiramate 400 mg/day group over the topiramate 50 mg/day group (Figure 1). The treatment effects with respect to time to first secure were consistent across various patient subgroups defined by age, sex, geographic region, baseline body weight, baseline secure type, time since diagnosis, and baseline AED use.

Figure 1: Kaplan-Meier Estimates of Cumulative Rates for Time to First Seizure in Study 1



#### Pediatric Patients 2 to 9 Years of Age

The conclusion that topiramate is effective as initial monotherapy in pediatric patients 2 The conclusion that topramate is effective as initial monotherapy in pediatric patients 2 to 9 years of age with partial-onset or primary generalized toms-clonk secures was based on a pharmacometric bridging approach using data from the controlled eplepsy trials described in labeling. This approach consisted of first showing a similar exposure response relationship between pediatric patients down to 2 years of age and adults when topiramate was given as adjunctive therapy. Similarity of exposure-response was also demonstrated in pediatric patients 6 to less than 16 years of age and adults when topiramate was given as initial monotherapy. Specific dosing in pediatric patients 2 to 9 years of age was derived from simulations utilizing plasma exposure ranges observed in pediatric and adult patients treated with topiramate initial monotherapy [*see Dosage and Adults tration ( 2.1)*].

#### 14.2 Adjunctive Therapy Epilepsy

# Adult Patients With Partial-Onset Seizures

Adult Patients with Partial-Unset Securits The effectiveness of topiramate as an adjunctive treatment for adults with partial-onset secures was established in six multicenter, randomized, double-blind, placebo-controlled trials (Studies 2, 3, 4, 5, 6, and 7), two comparing several dosages of topiramate and placebo and four comparing a single dosage with placebo, in patients with a history of partial-onset seizures, with or without secondarily generalized seizures.

participant secures, while a wallout secondary generalized secures. Patients in these studies were permitted a maximum of two anticipleptic drugs (AEDs) in addition to topiramate tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a pre-specified minimum number of partial-onset secures, with or without secondary generalization, during the baseline phase. Issues readoming signed to placebo or a specified dose of topiramate tablets in addition to their other AEDs.

ther other ALUS. Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless inbierance prevented increases. In the sixth study (Study 7), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day until the target dose of 200 mg/day was reached. After thration, patients entered a 4, 8 or 12-week stabilization period. The numbers of patients randomized to each dose and the actual mean and median doses in the stabilization period are shown in Table 12.

### Pediatric Patients 2 to 16 Years of Age with Partial-Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for pediatric patients 2 to 16 years of age with partial-onset seizures was established in a multicenter, randomized, double-blind, placebo-controlled trial (Study 8), comparing topiramate and placebo in patients with a history of partial-onset seizures, with or without secondarily generalized seizures (see Table 13).

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topiramate tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an Aeweck baseline phase. Patients who experienced at least six partial-onset seizures, with or without secondarily generalized seizures, during the baseline phase were randomly assigned to placebo or topiramund ossil to had to her other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drup beginning at 25 or 50 mg/day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225, or 400 mg/day based on patients' weight to approximate a dosage of 6 mg/kg/day was reached, unless intolerance prevented increases. After titration, patients entered an 8-week stabilization period.

# Patients With Primary Generalized Tonic-Clonic Seizures

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 2 years of age and older was established in a multicenter, randomized, double-blind, placebo-controlled trial (Study 9), comparing a single dosage of topiramate and placebo (see Table 13).

Patients in Study 9 were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topicamate or placebo. Patients were stabilized on optimum dosages of their concomtant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonci-colic sezures during the baseline phase were randomly assigned to placebo or topiramate in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg/day for four weeks; the dose was then

increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg/day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.

### Patients With Lennox-Gastaut Syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, double-blind, pacebo-controlled trial (Study 10) comparing a single dosage of topiramate with placebo in patients 2 years of age and older (see Table 12).

Platients in Study 10 were permitted a maximum, Patients in Study 10 were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topiramate or placebo. Patients who were experiencing at least 60 seizures per month before study entry were stabilized on optimum dosages of their concomkant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or topiramate in addition to their other AEDs. Active drug was titrated beginning at 1 mg/kg/day for a week; the dose was then increased to 3 mg/kg/day for one week, then to 6 mg/kg/day. After thration, patients entered an 8-week stabilization period.

The primary measures of effectiveness were the percent reduction in drop attacks and a parental global rating of seizure severity.

# Table 12: Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Adjunctive Trials in Adults with Partial-Onset Seizures a

					Target (mg/da		ate Dosag
Study	Stabilization Dose	Placebo <sup>b</sup>	200	400	600	800	1,000
2	N	42	42	40	41		
	Mean Dose	5.9	200	390	556		
	Median Dose	6.0	200	400	600		
3	N	44			40	45	40
	Mean Dose	9.7			544	739	796
	Median Dose	10.0			600	800	1,000
4	N	23		19			
	Mean Dose	3.8		395			
	Median Dose	4.0		400			
5	N	30			28		
	Mean Dose	5.7			522		
	Median Dose	6.0			600		
6	N	28				25	
	Mean Dose	7.9				568	
	Median Dose	8.0				600	
7	N	90	157				
	Mean Dose	8	200				
	Median Dose	8	200				

Brose-response studies were not conducted for other indications or pediatric partial-onset seizures.
 Braceho stages are given as the number of tablets. Placebo target dosages were as follows: Protocol 3 4 tablets/day. Protocols 1 and 4, 6 tablets/day. Protocols 5 and 6, 8 tablets/day.
 Protocol 2, 10 tablets/day.

In all adjunctive trials, the reduction in seizure rate from baseline during the entire double-blind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 13. As described above, a global improvement in seizure severity was also assessed in the Lennox-Gastaut trial.

Table 13: Efficacy Results in Double-Blind, Placebo-Controlled, Adjunctive Epilepsy Trials

Charles		opiramate					1.065	
Study#	#	Placebo	200	400	600	800	1,000	≈6 mg/
								kg/day*
	Onset Seizures Stu							
2	N	45	45	45	46			
	Median % Reduction	12	27 a	48 <sup>b</sup>	45 <sup>c</sup>			
	% Responders	18	24	44 <sup>d</sup>	46 <sup>d</sup>			
3	N	47			48	48	47	-
	Median % Reduction	2			41 <sup>c</sup>	41 <sup>c</sup>	36 <sup>c</sup>	
	% Responders	9			40 c	41 <sup>c</sup>	36 d	
4	N	24		23				
	Median % Reduction	1		41 e				
	% Responders	8		35 d				
5	M	30	1	-	30	-	-	L.
-	Median % Reduction	-12			46 f			-
	%	10			40 · 47 ·			
	Responders				470			
6	N	28				28		
	Median % Reduction	-21				24 c		
	% Responders	0				43 <sup>c</sup>		
7	N	91	168					
	Median % Reduction	20	44 <sup>c</sup>					
	% Responders	24	45 <sup>c</sup>					
Partial-	<b>Onset Seizures Stud</b>	lies in Pe	diatric	Patien	ts	-		
B	N	45						41
-	Median % Reduction	11						33 d
	% Responders	20						39
Primary	Generalized Tonic-	Clonic h						1
9	N	40	1	1		1	1	39
9	Median % Reduction	9						57 d
	%	20						57 - 56 c
	Responders	-			-	-		50 5
	-Gastaut Syndrome							
10	Ν	49						46
	Median % Reduction	-5						15 d
	% Responders	14						28 <sup>g</sup>
	Improvement in Seizure Severity <sup>j</sup>	28						52 <sup>d</sup>

Comparisons with placebo: <sup>a</sup>p=0.080; <sup>b</sup>p=0.010; <sup>c</sup>p=50.001; <sup>a</sup>p=0.052; <sup>a</sup>p=0.065; <sup>b</sup>p=0.010; <sup>c</sup>p=0.071; <sup>b</sup>Median % reduction and % responders are reported for PGTC seizures; <sup>1</sup>Median % reduction and % responders are reported for PGTC seizures; <sup>1</sup>Median % reduction and % responders for torog attacks, Le, tonic or atonic seizures precentage of subjects who were minimally, much, or very much improved from more the precent of the

baseline

baseline. \* For Studies 8 and 9, specified target dosages (<9.3 mg/kg/day) were assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; these dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day

Subset analyses of the antiepileptic efficacy of topiramate tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

In clinical trials for epilepsy, daily dosages were decreased in weekly intervals by 50 to 100 mg/day in adults and over a 2-to 8-week period in pediatric patients; transition was permitted to a new antiepilepit regimen when clinically indicated.

# 14.3 Preventive Treatment of Migraine

# Adult Patients

Adult Patients The results of 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, clinical trails established the effectiveness of topiramate in the preventive treatment of migraine. The design of both trials (Study 11 was conducted in the U.S. and Study 12 was conducted in the U.S. and Canada) was identical, enrolling patients with a history of migraine, mith or without aura, for at least 6 months, according to the International Headache Society (IHS) diagnostic criteria. Patients with a history of cluster headaches or basilar, optimalinopolegi, hemilogic, or transformed migraine headaches were excluded from the trials. Patients were required to have completed up to a 2-week washout of any prior migraine preventive medications before starting the baseline phase.

Patients who experienced 3 to 12 migraine headaches over the 4 weeks in the baseline phase were randomized to either topiramate 50 mg/day, 100 mg/day, 200 mg/day, or placebo and treated for a total of 26 weeks (6-week thration period and 18-week maintenance period). Treatment was initiated at 25 mg/day for one week, and then the daily dosage was increased by 25 mg increments each week until reaching the assigned target dose or maximum tolerated dose (administered twice daily).

Effectiveness of treatment was assessed by the reduction in migraine headache frequency, as measured by the change in 4-week migraine rate (according to migraines classified by links criteria) from the baseline phase to double-bind treatment period in each topramate treatment group compared to placebo in the intent-To-Treat (ITT) population.

In Study 11, a total of 469 patients (416 females, 53 males), ranging in age from 13 to 70 years, were randomized and provided efficacy data. Two hundred sixty-five patients completed the entire 25-week double-blind hoase. The median average daily dosages were 48 mg/day. 88 mg/day, and 132 mg/day in the target dose groups of topiramate 50, 100, and 200 mg/day, respectively.

So, too, and 200 ingrady, respectively. The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache frequency from baseline to the double-blind phase was -1.3, -2.1, and -2.2 in the topiramets 50, 100, and 200 mg/day groups, respectively, versus -0.8 in the placebo group (see Figure 2). The treatment differences between the topiramate 100 and 200 mg/day groups versus placebo were similar and statistically significant (p<0.001 for both comparisons).

In Study 12, a total of 468 patients (406 females, 62 males), ranging in age from 12 to 65 years, were randomized and provided efficacy data. Two hundred fifty-five patients completed the entire 26-week double-bind phase. The median average daily dosages were 47 mg/day, 86 mg/day, and 150 mg/day in the target dose groups of topiramate 50, 100, and 200 mg/day, respectively.


So, too, that 200 migraine beadched requency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache period frequency from baseline to the double-bind phase was 1.4, -2.1, and -2.4 in the topframate 50, 100, and 200 mg/day groups, respectively, versus 1.1 in the placebo group (see Figure 2). The differences between the topframate 100 and 200 mg/day groups, versus placebo were similar and statistically significant (p=0.008 and p <0.001, respectively).

In both studies, there were no apparent differences in treatment effect within age or gender subgroups. Because most patients were Caucasian, there were insufficient numbers of patients from different races to make a meaningful comparison of race.

For patients withdrawing from topiramate, daily dosages were decreased in weekly intervals by 25 to 50 mg/day.

# Figure 2: Reduction in 4-Week Migraine Headache Frequency

(Studies 11 and 12 for Adults and Adolescents)



#### Pediatric Patients 12 to 17 Years of Age

The effectiveness of topiramate for the preventive treatment of migraine in pediatric patients 12 to 17 years of age was established in a multicenter, randomized, double-blind, parallel group trial (Study 13). The study enrolled 103 patients (40 male, 63 female) 12 to 17 years of age with episodic migraine headaches with or without aura. Patient selection was based on HIS criteria for migraines (using proposed revisions to the 1988 IHS pediatric migraine criteria [IHS-R criteria]).

IHS pediatric migraine criteria [IHS-R criteria]). Patients who experienced 3 to 12 migraine attacks (according to migraines classified by patient reported diaries) and s14 headache days (migraine and non-migraine) during the 4-week prospective baseline period were randomized to either topiramate 50 mg/day, 100 mg/day, or placebo and treated for a total of 16 weeks (4-week thration period followed by a 12-week maintenance period). Treatment was initiated at 25 mg/day for one week, and then the daily dosage was increased by 25 mg increments each week until reaching the assigned target dose or maximum tolerated dose (administreed twice daily). Approximately 80% or more patients in each treatment group completed the study. The median average daily dosages were 45 and 79 mg/day in the target dose groups of topiramate 50 and 100 mg/day, respectively.

groups on topinations of treatment was assessed by comparing each topinamate treatment group to placebo (ITT population) for the percent reduction from baseline to the last 12 weeks of the double-bilind phase in the monthly migraine attack rate (primary endpoint). The percent reduction from baseline to the last 12 weeks of the double-bilind phase in average monthly migraine attack rate is shown in Table 14. The 100 mg topiramate dose produced a statistically significant treatment difference relative to placebo of 28% reduction from baseline in the monthly migraine attack rate. mate dose

The mean reduction from baseline to the last 12 weeks of the double-blind phase in average monthly attack rate, a key secondary efficacy endpoint in Study 13 (and the primary efficacy endpoint in Studies 11 and 12, of adults) was 3.0 for 100 mg topiramate does and 1.7 for placebo. This 1.3 treatment difference in mean reduction from baseline of monthly migraine rate was statistically significant (p = 0.0087).

# Table 14: Percent Reduction from Baseline to the Last 12 Weeks of Double-Blind Phase in Average Monthly Attack Rate: Study 13 (Intent-to-Treat Analysis Set)

Category	Placebo	Topiramate 50 mg/day	Topiramate 100 mg/day
	(N=33)	(N=35)	(N=35)
Baseline			
Median	3.6	4.0	4.0
Last 12 Weeks of Doub	le-Blind Pha	se	
Median	2.3	2.3	1.0
Percent Reduction (%)			
Median	44.4	44.6	72.2
P-value versus		0.7975	0.0164 <sup>c</sup>
Placebo <sup>a,b</sup>			

P-values (two-sided) for comparisons relative to placebo are generated by applying an ARCOVA model on ranks that includes subjects's statified age at baseline, treatment group, and analysis center as factors and monthly migraine attack rate during baseline period as a covariate.
P-values for the dose groups are the adjusted p-value according to the Hochberg multiple comparison procedure.

<sup>c</sup>Indicates p-value is <0.05 (two-sided).

# 16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

#### Topiramate tablets .USP

Topiramate tablets, USP are available in the following strengths and colors: 100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side and are available in

Bottles of 30 NDC: 80425-0373-01

Bottles of 60 NDC: 80425-0373-02

Bottles of 90 NDC: 80425-0373-03

PHARMACIST: Dispense in a tight container as defined in the USP. Use child-resistant closure (as required).

# 16.2 Storage and Handling

Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature]. Protect from moisture.

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

## Eve Disorders

Instruct patients taking topiramate tablets to seek immediate medical attention if they experience burred vision, visual disturbances, or periorbital pain [see Warnings and Precautions (5.1, 5.2)].

### Oligohidrosis and Hyperthermia

Cosely monitor topiramate-treated patients, especially pediatric patients, for evidence of decreased sweating and increased body temperature, especially in hot weather. Counsel patients to contact their healthcare professionals immediately if they develop a high or persistent fever, or decreased sweating (see Warnings and Precautions ( 5.3)).

### Metabolic Acidosis

Warn patients about the potential significant risk for metabolic acidosis that may be asymptomatic and may be associated with adverse effects on kidneys (e.g., kidney stones, nephrocakinosis), bomes (e.g., osteoprosis, osteomalacia, and/or rickets in children), and growth (e.g., growth delay/retardation) in pediatric patients, and on the fetus (see Warnings and Precautions (5-4), Use in Specific Populations (6-1)).

## Suicidal Behavior and Ideation

Counsel patients, their caregivers, and families that AEDs, including topiramate tablets, may increase the risk of suicidal thoughts and behavior, and advise of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about self-harm. Instruct patients to immediately report behaviors of concern to their healthcare providers (see Warnings and Precautions (5.5)).

# Interference with Cognitive and Motor Performance

Warn patients about the potential for somolence, dizziness, confusion, difficulty concentrating, or visual effects, and advise patients not to drive or operate machinery until they have gained sufficient experience on topiramate tablets to gauge whether it adversely affects their mental performance, motor performance, and/or vision [see Warnings and Precautions ( 5.6)].

Even when taking topiramate tablets or other anticonvulsants, some patients with epilepsy will continue to have unpredictable seizures. Therefore, advise all patients taking topiramate tablets for epilepsy to exercise appropriate caution when engaging in any topramate tablets for epilepsy to exercise appropriate caution when engaging in any activities where loss of consciousness could result in serious danger to themselves or those around hem (including swimming, driving a car, climbing in high places, etc.). Some patients with refractory epilepsy will need to avoid such activities altogether. Discuss the appropriate level of caution with patients, before patients with epilepsy engage in such activities.

#### Fetal Toxicity

Teta ToxIcty Inform pregnant women and women of childbearing potential that use of topiramate tablets during pregnancy can cause fetal harm. Topiramate increases the risk of major congenial maformations, including but not limited to cleft lip and/or cleft palate (arai clefts), which occur early in pregnancy before many women know they are pregnant. Also inform patients that infants exposed to topiramate monotherapy in uteromay be SGA (see Use in Specific Populations (8.1)). There may also be risks to the fetus from chronic metabolic acidosis with use of topiramate tablets during pregnancy (see Warnings and Precautions (5.7). Use in Specific Populations (8.1)). When appropriate, course) pregnant women and women of childbearing potential about alternative therapeutic options.

Advise women of childbearing potential who are not planning a pregnancy to use effective contraception while using topiramate tablets, keeping in mind that there is a potential for decreased contraceptive efficacy when using estrogen-containing or progestin-only contraceptives with topiramate (see Drug Interactions (7.4))

Encourage pregnant women using topiramate tablets, to enroll in the North American Antiepleptic Drug (NAAED) Pregnancy Registry. The registry is collecting information about the safety of antiepileptic drugs during pregnancy [see Use in Specific Populations (8.1)].

# Decrease in Bone Mineral Density

Inform the patient or caregiver that long-term treatment with topiramate can decrease bone formation and increase bone resorption in children [see Warnings and Precautions ( 5.9)].

Negative Effects on Growth (Height and Weight)

Discuss with the patient or caregiver that long-term topiramate treatment may attenuate growth as reflected by slower height increase and weight gain in pediatric patients [see Warnings and Precautions (5.10)].

#### Serious Skin Reactions

Inform patients about the signs of serious skin reactions. Instruct patients to immediately inform their healthcare provider at the first appearance of skin rash [see Warnings and Precautions ( 5.11)].

#### Hyperammonemia and Encephalopathy

Warn patients about the possible development of hyperammonemia with or without encephalopathy. Although hyperammonemia may be asymptomatic, clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy and/or vomiting. This hyperammonemia and encephalopathy can develop with topiramate tablets treatment alone or with topiramate tablets treatment with concomitant valproic acid (VPA). Instruct patients to contact their physician if they develop unexplained lethargy, vomiting, or changes in mental status [see Warnings and Precautions ( 5.12)].

Kidnev Stones

Instruct patients, particularly those with predisposing factors, to maintain an adequate fluid intake in order to minimize the risk of kidney stone formatio n [see Warnings and Precautions ( 5.13)].

# Instructions for a Missing Dose

Instruct patients that if they miss a single dose of topiramate tablets, it should be taken as soon as possible. However, if a patient is within 6 hours of taking the next scheduled dose, tell the patient to wait until then to take the usual dose of topiramate tablets, and to skip the missed dose. Tell patients that they should not take a double dose in the event of a missed dose. Advise patients to contact their healthcare provider if they have missed more than one dose.

Manufactured by:

Cipla Ltd., Kurkumbh-413802, Maharashtra, India

Manufactured for:

## Cipla USA, Inc.

10 Independence Boulevard, Suite 300 Warren, NJ 07059

Revised: 05/2023

## SPL MEDGUIDE

#### Topiramate (toe pir'a mate) Tablets USP

# What is the most important information I should know abouttopiramate tablets?

- Topiramate tablets maycause eye problems.Serious eye problems include:
  any sudden decrease in vision with or without eye pain and redness.
  a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma).
  These eye problems can lead to permanent loss of vision if not treated.
  You should call your healthcare provider right away if you have any new eye symptoms, including any new problems with your vision.

Topiramate tablets may cause decreased sweating and increased body temperature (fever).People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition. If a high fever, a fever that does not go away, or decreased sweating develops, call your heathcare provider right away.

# Topiramate tablets can increase the level of acid in your blood (metabolic acidosis).If left untreated, metabolic acidosis can cause brittle or soft bones

(osteoporos), osteomator, osteopanio, osteoponio, kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms.

feel tired
feel tired
not feel hungry (loss of appetite)
feel changes in heartbeat
have trouble thinking clearly

Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with topiramate tablets. If you are pregnant, you should talk to your healthcare provider about whether you have metabolic acidosis.

# Like other antiepileptic drugs, topiramate tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

# Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: • thoughts about suicide or dying

- attempts to commit suicide
- new or worse depression new or worse anxiety feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia) thoughts about suicide or dying
- attempts to commit suicide
- new or worse depression new or worse anxiety
- feeling agitated or restless
- panic attacks trouble sleeping (insomnia)

Do not stoptopiramate tablets without first talking to a healthcare provider. Stopping topiramate tablets suddenly can cause serious problems. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other accession.

- How can I watch for early symptoms of suicidal thoughts and actions?
  Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
  Keep all follow-up visits with your healthcare provider as scheduled.
  Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

#### Topiramate tablets can harm your unborn baby.

- Topiramate tablets can harm your unborn baby. If you take topiramate tablets during pregnancy, your baby has a higher risk for birth defects including cleft ij and cleft palate. These defects can begin early in pregnancy, even before you know you are pregnant. Birth defects may happen even in children born to women who are not taking any medicines and do not have other risk factors. There may be other medicines to treat your condition that have a lower chance of birth defects. All women of childbearing age should talk to their healthcare providers about using other possible treatments instead of topiramate tablets. If the decision is made to use topiramate tablets, you should use effective birth control (contraception) unless you are planning to become pregnant. You should talk to your doctor about the best kind of birth control to use while you are taking topiramate tablets. Tell your healthcare provider right away if you become pregnant. Hy our lot take topiramate tablets while you are reginant.
- If you take topiramate during pregnancy, your baby may be smaller than expected at birth. The long-term effects of this are not known. Talk to your healthcare provider if
- birth. The long-term effects of this are not known. Tak to your healthcare provider you have questions about this risk during pregnancy. Metabolic acidosis may have harmful effects on your baby. Tak to your healthcare provider if topiramet tablet has caused metabolic acidosis during your pregnancy. Pregnancy Registry: If you become pregnant while taking topiramate tablets, tak to your healthcare provider about registering with the North American Antelepieptic Dr Pregnancy Registry. You can enrol in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of topiramate tablets and other antiepileptic drugs during pregnancy. Drug

# Topiramate tablets may decrease the density of bones when used over a long period.

# Topiramate tablets may slow height increase and weight gain in children and adolescents when used over a long period.

# What istopiramate tablets?

#### Topiramate tablets is a prescription medicine used:

- In the context of a prescription interact in ease.
   Is to treat certain types of seizures (partial-onset selzures and primary generalized tonic-clonic seizures) in adults and children 2 years and older,
   with other medicines to treat certain types of seizures (partial-onset seizures,
- wich oscie mediatal to il cella claration ypes of secures jubitational secure secures y primary generalized tonic-clonic secures, and secures associated with Lennox-Gastaut syndrome in adults and children 2 years and older,
   to prevent migraine headaches in adults and adolescents 12 years and older.

- Before taking topiramate tablets, tell your healthcare provider about all of your medical conditions, including if you: have or have had depression, mood problems, or suicidal thoughts or behavior.
- have kidney problems, have kidney stones, or are getting kidney dialysis have a history of metabolic acidosis (too much acid in the blood).
- have liver proble
- have weak, brittle, or soft bones (osteomalacia, osteoporosis, osteopenia, or decreased bone density).
- have lung or breathing problems have eye problems, especially gla have diarrhea.
- ecially glaucoma

#### have a growth problem are on a diet high in fat and low in carbohydrates, which is called a ketogenic diet.

- are bring surgery. are pregnant or plan to become pregnant. are breasteding or plan to become pregnant. are breastfeeding or plan to breastfeed. Topiramate tablets passes into breast milk. are undastreturing on plant to incastretur. Ioplantatic taxets passes into the plantameter Breastfed babies may be sleepy or have diarrhea. It is not known if the plantameter that passes into breast milk can cause other serious harm to your baby. Talk to your healthcare provider about the best way to feed your baby if you taby. Talk to jour

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vikamins, and herbal supplements. Topiramate and other medicines may affect each other causing side effects.

- Especially tell your healthcare provider if you take: Valproic acid (such as DEPAKENE or DEPAKOTE). any medicines that impair or decrease your thinking, concentration, or muscle
- any measure that may be declease you training, concentration, or makes coordination. birth control that contains hormones (such as pills, implants, patches or injections). Topiramate tablets may make your birth control less effective. Tel your healthcare provider if your menstrual bleeding changes while you are using birth control and topiramate tablets

Ask your healthcare provider if you are not sure if your medicine is listed above. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without taking with your healthcare provider.

- How should I taketopiramate tablets?
  Take topiramate tablets exactly as prescribed.
  Your heathcare provider may change your dose. Do notchange your dose without taking to your heathcare provider.
  Take topiramate tablets whole. Do notchew the tablets. They may leave a bitter taste

- taste. **Do not**store any medicine and food mixture for later use. Topiramate tablets can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent kidney stones while taking topiramate tablets. If you take too much topiramate tablets, cal your healthcare provider right away or go to the nearest emergency room.
- If you miss a single dose of topiramate tablets, take it as soon as you can. However
- If you miss a single dose of topramate tablets, take it as soon as you can. However, if you are within 6 hours of taking your next scheduled dose, wait until them to take your usual dose of topiramate tablets, and skip the missed dose. **Do not**double your dose. If you have missed more than one dose, you should call your healthcare provider for advice. **Do not**stop taking topiramate tablets without taking to your healthcare provider. Stopping topiramate tablets suddenly may cause serious problems. If you have epileps and you stop taking topiramate tablets suddenly you may have setures that do not stop. Your healthcare provider will tell you how to stop taking topiramate tablets, slowly. tablets slowly Your healthcare provider may do blood tests while you take topiramate tablets

# What should I avoid while taking topiramate tablets?

- You should not drink alcohol while taking topiramate tablets. Topiramate tablets and alcohol can affect each other causing side effects such as sleepiness and dizziness. Do not drive a car or operate machinery until you know how topiramate tablets affects you. Topiramate tablets can slow your thinking and motor skills, and may

#### affect vision.

# What are the possible side effects oftopiramate tablets?

# Topiramate tablets may cause serious side effects including:

See "What is the most important information I should know about topira tablets?"

- high blood ammonia levels. High ammonia in the blood can affect your mental activities, slow your alertness, make you feel tired, or cause vomiting. This has happened when topiramate tablets is taken with a medicine called valproic acid (DEPAKENE and DEPAKOTE).
- (DEPARKINE and DEPARK) IE). Effects on thinking and alertness. Topiramate tablets may affect how you think and cause confusion, problems with concentration, attention, memory, or speech. Topiramate tablets may cause depression or mood problems, tiredness, and
- sleepines. Dizziness or loss of muscle coordination. Servicus skin reactions. Topicamate tables may cause a severe rash with bisters and peeling skin, especially around the mouth, nose, eyes, and genitals (Stevens-johnson syndrome). Topicamate tables may also cause a rash with bisters and peeling skin over much of the body that may cause death (toxic epidermal necrolysis). Call your healthcare provider right away if you develop a skin rash or bisters.
- Discrets.
  Kidney stones.Drink plenty of fluids when taking topiramate tablets to decrease your chances of getting kidney stones.
  Low body temperature. Taking topiramate tablets when you are also taking valproix acid can cause a drop in body temperature to less than 95 °F, or can cause triedness, confusion, or coma.

Call your healthcare provider right away if you have any of the symptoms above

- Car you nearcare provide right any i you need by you we The most common side effects of topiramate tablets include: tingling of the arms and legs (paresthesia) not feeling hungry nausea a change in the way foods taste diarrhea

- weight loss nervousness
- nervousness upper respiratory tract infection speech problems tiredness
- dizziness

- dizziness sleepiness/drowsiness slow reactions difficulty with memory pain in the abdomen fever
- abnormal vision

decreased feeling or sensitivity, especially in the skin

Tel your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of Topiramate. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Cipla Ltd. India. at 1-866-604-3268.

- How should I store topiramate tablets? Store Topiramate tablets USP at room temperature, 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature].
- Keep Topiramate tablets in a tightly closed container.
  Keep Topiramate tablets dry and away from moisture.

# Keep Topiramate and all medicines out of the reach of children.

General information about the safe and effective use of topiramate tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Topiramate for a condition for which it was not prescribed. Do not give topiramate tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about topiramate tablets that is written for health professionals.

# What are the ingredients in topiramate tablets?

Active ingredient:Topiramate USP

Tactive ingredients:
 Tablets - contain hypromellose, lactose monohydrate, magnesium stearate, microcrystaline cellulose, polyethylene glycol, polysorbate 80, pre gelatinized starch, sodium starch glycolate and titanium dioxide. In addition, the 25 mg also contains FD&C Blue #2; the 50 mg and 100 mg also contain red iron oxide and yellow iron oxide; and the 200 mg also contains red iron oxide.

Disclaimer: Other brands listed are the registered trademarks of their respective owners and are not trademarks of Cipla Limited.

# Manufactured by:

Cipla I td...

Kurkumbh-413802

Maharashtra, India

Manufactured for:

Cipla USA, Inc.10 Independence Boulevard,

Suite 300

Warren, NJ 07059 For more information, call 1-866-604-3268.

This Medication Guide has been approved by the U.S. Food and Drug Administration

## Revised: 05/2023

Packed By: AdvancedRx NashvilleTN, 37217		Store et 30°-25°C (55°-77°F) Galais, failed las MOHET Stanks al bai deg la reparat aller has la palad la whor i angreschie	Pecked By: AdvancedRX NeetvilleTH, 37217		Shore at 20°-25°C (68° Code: Felend in PROVIDE Evolution Felend in PROVIDE State of the provide the fee	
OPIRAMATE 100	MG TABLE	r	TOPIRAMATE 100	MG TABLE	г	
ompare to TOPAM/ IDC: 80425-0373-0 ot: XXXXXX Expir	1 Source NI	#30 00: 69097-0124-03 125	Compare to TOPAM NDC: 80425-0373-6 Lot: XXXXXX Expire	2 Source NE		
		Rx Only			Only	
OPTRAMATE 100MG TABL DCI 80425-0373-01 NVFCE NDCI 89097-0124-1 N: XXXXXXX 8xp.8/30/2		CIPLA USA, INC. S/N: 000000203208	TOPERAMATE 100HG TABL NDCI 86425-0375-02 Severce NDC: 69097-0124- Lot: YXXXXX Exp:6/30/20		CIPLA USA, INC S/N: 00000020	
AdvancedRx NeshvilleTN, 37217	A STATE	Share at 20°-25°C (06°-77°F) Socker, Televillas Hittelitta foede at the Arc in stranger and the the patient for white it was presided				
OPIRAMATE 100	MG TABLE	т				
ompare to TOPAM IDC: 80425-0373-0 ot: XXXX Expires: 1	3 Source N	#90 DC: 69097-0124-03				
	Rx Onl	v				
OPTRAMATE 100NG TABL DC: 80425-0373-03 ource NDC: 69097-0124- 4/ XXXX 8xp:6/30/2025		CIPLA USA, INC. S/N: 000000203212				
OPIRAM						
Product In	format	ion				
Product Type	•	HUMAN P DRUG	RESCRIPTION	Item Co (Source		NDC:80425- 124)
	ninistra	tion OBAI				

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TOPIRAMATE (UNII: 0H73WJ391) (TOPIRAMATE - UNII:0H73WJ391)	TOPIRAMATE	100 mg

Inactive Ingredients

RATE (UNII: EWQ57Q8I5X) 08232NY35I)		
08232NY35I)		
RYSTALLINE (UNII: OP1R32D61U)		
COLATE TYPE A POTATO (UNII: 5856J3G2	(A2)	
TE (UNII: 70097M6I30)		
0 (3 MPA.S) (UNII: 0VUT3PMY82)		
0 (6 MPA.S) (UNII: 0WZ8WG20P6)		
JNII: 15FIX9V2JP)		
COL 400 (UNII: B697894SGQ)		
NII: 60ZP39ZG8H)		
W (UNII: EX43802MRT)		
JNII: 1K09F3G675)		
teristics		
range	Score	no score
	Size	9mm
tOUND (Circular, biconvex)		
(OUND (Circular, biconvex)	Imprint Code	124:Cipla
(UUND (Circular, biconvex)	Imprint Code	124;Cipla
	Imprint Code	124;Cipla
IOUND (Circular, biconvex) Package Description		
	Marketing Start	Marketing End
Package Description	Marketing Start Date	Marketing End
Package Description	Marketing Start Date	Marketing End
Package Description 7 n 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination	Marketing Start Date 02/05/2024 02/05/2024	Marketing End
Package Description 7 n 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination 0 1 1 80'TLE: Type 0: Not a Combination	Marketing Start Date 02/05/2024 02/05/2024	Marketing End
Package Description Din 1 80TTLE: Type 0: Not a Combination oduct Din 1 80TTLE: Type 0: Not a Combination oduct	Marketing Start Date 02/05/2024 02/05/2024 02/05/2024	Marketing End Date
	0 (5 MPAS) (UNI: 0VUT3PHY2) 0 (6 MPAS) (UNI: 0VUZ8WC20P6) INI: 1570972P) COL 400 (UNI: 86978945GQ) INI: 150939(S9N) W (UNI: EX43802MRT) INI: 150939675) Exeristics	0 (0 MPA.5) (UMI: 0/UT3PWR2) 0 (6 MPA.5) (UMI: 0/Z3WG20P6) NIII: 1570/2/P) 00 (0 (UMI: 6678945G0) W (UMI: 66278945G0) W (UMI: EX438024MRT) NIII: 1x06796675) Exeristics

 Name
 Address
 ID/FEI
 Business Operations

 Advanced Rx Pharmacy of Tennessee, LLC
 117023142
 repack(80425-0373)

Revised: 2/2024

Advanced Rx Pharmacy of Tennessee, LLC